Targeting ubiquitin signaling for cancer immunotherapy

Cancer immunotherapy has become an attractive approach of cancer treatment with tremendous success in treating various advanced malignancies. The development and clinical application of immune checkpoint inhibitors represent one of the most extraordinary accomplishments in cancer immunotherapy. In a...

Full description

Saved in:
Bibliographic Details
Published inSignal transduction and targeted therapy Vol. 6; no. 1; pp. 16 - 15
Main Authors Zhou, Xiaofei, Sun, Shao-Cong
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 13.01.2021
Nature Publishing Group
Subjects
631/250/251
631/250/580
Cancer
Cancer Research
Cell Biology
Deubiquitinating Enzymes - immunology
Humans
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy
Internal Medicine
Medicine
Medicine & Public Health
Neoplasm Proteins - immunology
Neoplasms - immunology
Neoplasms - therapy
Oncology
Pathology
Review
Review Article
Ubiquitin - immunology
Ubiquitin-Protein Ligases - immunology
Ubiquitination - immunology
Online AccessGet full text

Cover

Abstract Cancer immunotherapy has become an attractive approach of cancer treatment with tremendous success in treating various advanced malignancies. The development and clinical application of immune checkpoint inhibitors represent one of the most extraordinary accomplishments in cancer immunotherapy. In addition, considerable progress is being made in understanding the mechanism of antitumor immunity and characterizing novel targets for developing additional therapeutic approaches. One active area of investigation is protein ubiquitination, a post-translational mechanism of protein modification that regulates the function of diverse immune cells in antitumor immunity. Accumulating studies suggest that E3 ubiquitin ligases and deubiquitinases form a family of potential targets to be exploited for enhancing antitumor immunity in cancer immunotherapy.
AbstractList Cancer immunotherapy has become an attractive approach of cancer treatment with tremendous success in treating various advanced malignancies. The development and clinical application of immune checkpoint inhibitors represent one of the most extraordinary accomplishments in cancer immunotherapy. In addition, considerable progress is being made in understanding the mechanism of antitumor immunity and characterizing novel targets for developing additional therapeutic approaches. One active area of investigation is protein ubiquitination, a post-translational mechanism of protein modification that regulates the function of diverse immune cells in antitumor immunity. Accumulating studies suggest that E3 ubiquitin ligases and deubiquitinases form a family of potential targets to be exploited for enhancing antitumor immunity in cancer immunotherapy.
Abstract Cancer immunotherapy has become an attractive approach of cancer treatment with tremendous success in treating various advanced malignancies. The development and clinical application of immune checkpoint inhibitors represent one of the most extraordinary accomplishments in cancer immunotherapy. In addition, considerable progress is being made in understanding the mechanism of antitumor immunity and characterizing novel targets for developing additional therapeutic approaches. One active area of investigation is protein ubiquitination, a post-translational mechanism of protein modification that regulates the function of diverse immune cells in antitumor immunity. Accumulating studies suggest that E3 ubiquitin ligases and deubiquitinases form a family of potential targets to be exploited for enhancing antitumor immunity in cancer immunotherapy.
Cancer immunotherapy has become an attractive approach of cancer treatment with tremendous success in treating various advanced malignancies. The development and clinical application of immune checkpoint inhibitors represent one of the most extraordinary accomplishments in cancer immunotherapy. In addition, considerable progress is being made in understanding the mechanism of antitumor immunity and characterizing novel targets for developing additional therapeutic approaches. One active area of investigation is protein ubiquitination, a post-translational mechanism of protein modification that regulates the function of diverse immune cells in antitumor immunity. Accumulating studies suggest that E3 ubiquitin ligases and deubiquitinases form a family of potential targets to be exploited for enhancing antitumor immunity in cancer immunotherapy.Cancer immunotherapy has become an attractive approach of cancer treatment with tremendous success in treating various advanced malignancies. The development and clinical application of immune checkpoint inhibitors represent one of the most extraordinary accomplishments in cancer immunotherapy. In addition, considerable progress is being made in understanding the mechanism of antitumor immunity and characterizing novel targets for developing additional therapeutic approaches. One active area of investigation is protein ubiquitination, a post-translational mechanism of protein modification that regulates the function of diverse immune cells in antitumor immunity. Accumulating studies suggest that E3 ubiquitin ligases and deubiquitinases form a family of potential targets to be exploited for enhancing antitumor immunity in cancer immunotherapy.
ArticleNumber 16
Author Sun, Shao-Cong
Zhou, Xiaofei
Author_xml – sequence: 1
  givenname: Xiaofei
  orcidid: 0000-0002-9289-2215
  surname: Zhou
  fullname: Zhou, Xiaofei
  organization: Department of Immunology, The University of Texas MD Anderson Cancer Center
– sequence: 2
  givenname: Shao-Cong
  orcidid: 0000-0001-7353-9400
  surname: Sun
  fullname: Sun, Shao-Cong
  email: ssun@mdanderson.org
  organization: Department of Immunology, The University of Texas MD Anderson Cancer Center, The University of Texas Graduate School of Biomedical Sciences
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33436547$$D View this record in MEDLINE/PubMed
BookMark eNp9Uk1P3TAQtCqqQil_oIfqSb30knb9GftSqUKlRULqhZ4t23GCnxL7YSeV-Pf4EaDAgZNX65nxeHfeo4OYokfoI4avGKj8VhimijRAoAFgBDfkDToiwFVDBeUHT-pDdFLKFgCwoG3L2Tt0SCmjgrP2CIlLkwc_hzhsFhuul1DLTQlDNOO-16e8cSY6nzdhmpaY5iufze7mA3rbm7H4k_vzGP09-3l5-ru5-PPr_PTHReMEiLnh3Kue9p2TXCllhHEMO0U9c1Zih7FlxllrpKUCpPLVk1NYdYRSJTpsMT1G56tul8xW73KYTL7RyQR910h50CbPwY1ed4or4qklVvVMEi9b4EA7QoghoISrWt9Xrd1iJ985H-dsxmeiz29iuNJD-qdbCYwpqAJf7gVyul58mfUUivPjaKJPS9GE1fECtJxW6OcX0G1ach3qigJVV8Yq6tNTR49WHtZTAWQFuJxKyb5_hGDQ-xjoNQa6xkDfxUCTSpIvSC7MZg5p_6swvk6lK7XUd-Lg83_br7BuAc1YxRE
CitedBy_id crossref_primary_10_1038_s41419_023_06000_x
crossref_primary_10_1016_j_bbamcr_2024_119773
crossref_primary_10_1016_j_csbj_2023_10_020
crossref_primary_10_1016_j_apsb_2024_04_022
crossref_primary_10_15252_embr_202357828
crossref_primary_10_1016_j_gendis_2023_101158
crossref_primary_10_1126_sciadv_adq6830
crossref_primary_10_3390_immuno3010006
crossref_primary_10_1039_D4BM01532K
crossref_primary_10_4049_jimmunol_2100303
crossref_primary_10_3389_fonc_2021_752604
crossref_primary_10_1186_s12967_024_05245_0
crossref_primary_10_18632_aging_204650
crossref_primary_10_3390_biomedicines11123240
crossref_primary_10_3389_fimmu_2023_1123244
crossref_primary_10_3390_ijms24098441
crossref_primary_10_1038_s44318_024_00201_6
crossref_primary_10_1038_s41598_023_41554_y
crossref_primary_10_3390_cancers15113009
crossref_primary_10_1016_j_ijrobp_2023_12_003
crossref_primary_10_2174_1566524023666230510101525
crossref_primary_10_1016_j_ejmech_2024_117034
crossref_primary_10_1016_j_semcancer_2025_02_004
crossref_primary_10_1038_s41419_025_07372_y
crossref_primary_10_1038_s41467_023_35958_7
crossref_primary_10_1002_advs_202304755
crossref_primary_10_1016_j_ejmech_2023_115875
crossref_primary_10_1186_s12885_025_13473_w
crossref_primary_10_3390_cancers14143478
crossref_primary_10_3390_cells10123309
crossref_primary_10_1016_j_ebiom_2022_103941
crossref_primary_10_1200_JCO_23_01488
crossref_primary_10_1038_s41577_023_00867_9
crossref_primary_10_1038_s41417_021_00371_z
crossref_primary_10_1016_j_heliyon_2024_e29387
crossref_primary_10_3390_biom13121724
crossref_primary_10_1186_s13062_024_00497_8
crossref_primary_10_1186_s13578_022_00870_y
crossref_primary_10_3389_fonc_2024_1446522
crossref_primary_10_1038_s41419_023_06265_2
crossref_primary_10_1007_s13258_022_01238_9
crossref_primary_10_1038_s41389_024_00524_3
crossref_primary_10_31083_j_fbl2811304
crossref_primary_10_3389_fcell_2021_699304
crossref_primary_10_1136_jitc_2024_009860
crossref_primary_10_1186_s40164_024_00552_0
crossref_primary_10_1186_s13062_024_00562_2
crossref_primary_10_1038_s41419_023_06322_w
crossref_primary_10_1039_D2BM00079B
crossref_primary_10_3892_or_2022_8335
Cites_doi 10.1002/eji.201444512
10.1038/ncomms13559
10.18632/oncotarget.18360
10.1074/jbc.M112.374744
10.1038/nm0396-338
10.4049/jimmunol.182.2.860
10.1038/nrc.2017.17
10.1038/nm.3111
10.1038/nature12998
10.1189/jlb.1211623
10.1371/journal.pone.0189744
10.4049/jimmunol.1700273
10.1016/j.cell.2018.01.004
10.1038/ni.3347
10.1002/eji.200737902
10.1073/pnas.1312994110
10.1007/s11684-018-0651-y
10.1038/ni.3258
10.1038/ni1564
10.1371/journal.pone.0019047
10.1038/35003235
10.1016/j.csbj.2019.01.009
10.1038/s41598-020-62076-x
10.1038/s41467-017-00324-x
10.1038/s41590-020-0632-6
10.1038/ni.2135
10.1371/journal.pbio.1000017
10.4049/jimmunol.0803313
10.1136/esmoopen-2019-000614
10.1038/ni.3641
10.18632/oncotarget.8980
10.1182/blood-2006-04-017210
10.1016/j.it.2014.11.001
10.1186/s40425-019-0750-6
10.1111/imr.12789
10.1038/cddis.2017.102
10.1084/jem.20101123
10.1038/s41577-019-0210-z
10.1080/2162402X.2017.1368605
10.1146/annurev-cancerbio-030419-033428
10.1038/s41586-018-0756-0
10.1074/jbc.M112.383265
10.1038/s41420-020-0292-1
10.1111/imr.12303
10.1080/2162402X.2018.1471440
10.1016/j.immuni.2010.05.002
10.1084/jem.20100004
10.1146/annurev.biochem.67.1.425
10.4049/jimmunol.1302312
10.1042/EBC20170035
10.4049/jimmunol.176.11.6454
10.1016/j.ccell.2018.05.004
10.4049/jimmunol.1900171
10.4049/jimmunol.1401548
10.1146/annurev.immunol.021908.132706
10.1016/j.ejmech.2020.112107
10.1111/imr.12033
10.1038/s41467-017-00252-w
10.3389/fped.2014.00075
10.1172/JCI41991
10.3389/fimmu.2017.00042
10.1016/j.immuni.2006.08.017
10.1038/nrm2162
10.1038/ni1561
10.1038/s41598-019-56208-1
10.1126/science.1059780
10.1093/intimm/dxh184
10.1038/nri.2016.62
10.1016/S1074-7613(03)00351-0
10.1073/pnas.1406259111
10.1111/imr.12311
10.1038/nrc2502
10.1084/jem.20061699
10.1016/j.immuni.2016.04.019
10.1038/nature03555
10.1016/j.immuni.2010.02.004
10.1038/s41467-019-12384-2
10.1038/ncomms6930
10.1038/ni1147
10.1016/j.ccell.2017.10.003
10.1074/jbc.RA118.003857
10.1038/s41467-019-09525-y
10.1084/jem.20151426
10.1074/jbc.M808222200
10.1073/pnas.0908957106
10.1038/nri1148
10.4049/jimmunol.0901679
10.1084/jem.20182164
10.1128/JVI.78.3.1109-1120.2004
10.1007/s00281-010-0197-9
10.1073/pnas.0708874105
10.1016/S1074-7613(03)00084-0
10.1038/nature02273
10.1126/scisignal.aab2724
10.1038/nature23669
10.1038/ni.2267
10.1038/nrd.2018.169
10.1016/j.ebiom.2016.10.018
10.1016/j.immuni.2010.10.013
10.1038/nri1248
10.2353/ajpath.2009.080861
10.1038/cr.2016.40
10.1016/j.immuni.2013.01.011
10.1016/j.cell.2015.03.030
10.1016/j.tcb.2009.05.005
10.1111/j.1600-065X.2012.01100.x
10.1146/annurev.immunol.23.021704.115839
10.1016/j.coi.2014.12.009
10.1074/jbc.M109.095190
10.1021/acs.jmedchem.9b01138
10.1016/j.apsb.2019.08.010
10.4049/jimmunol.1402434
10.1007/s00262-016-1829-2
10.1038/nm1721
10.1016/j.immuni.2019.01.014
10.1038/nri.2017.52
10.1111/j.1600-065X.2011.01088.x
10.1158/1078-0432.CCR-12-3603
10.4049/jimmunol.1003411
10.1038/s41590-018-0265-1
10.1038/363552a0
10.1146/annurev-immunol-032713-120156
10.1038/ni.2390
10.1038/nature06253
10.1016/j.immuni.2015.05.016
10.1042/BCJ20160582
10.1084/jem.20092203
10.3389/fimmu.2018.01849
10.1073/pnas.092675799
10.1016/S1097-2765(04)00236-9
10.4049/jimmunol.1201993
10.1016/j.apsb.2019.12.008
10.1016/j.cell.2011.07.033
10.4049/jimmunol.1801133
10.1146/annurev-immunol-042718-041717
10.4049/jimmunol.173.2.1059
10.1038/ni.1777
10.1007/s00281-016-0611-z
10.1073/pnas.1507981112
10.1111/imr.12432
10.4049/jimmunol.1201620
10.1038/35003228
10.1038/nature23643
10.4049/jimmunol.1203010
10.1172/JCI29472
10.1074/jbc.RA118.005802
10.1186/s12964-020-00612-y
10.1038/nri3712
10.1007/s00281-016-0599-4
10.1038/nri3254
10.2147/OTT.S212317
10.1016/j.coi.2016.12.005
10.1038/nrc.2017.105
10.1038/s41568-020-0272-z
10.1038/ni.2090
10.1016/j.immuni.2014.09.008
10.1038/s41577-019-0127-6
10.1016/j.immuni.2016.05.002
10.1073/pnas.140129797
10.1002/eji.201445342
10.1084/jem.20131019
10.1016/j.immuni.2013.08.006
10.1016/j.coi.2019.12.005
10.1016/j.immuni.2013.07.004
10.1074/jbc.M111.292961
10.1016/j.immuni.2011.08.012
10.1084/jem.20062694
10.3389/fphar.2018.00536
10.1084/jem.20161524
10.4161/21624011.2014.958951
10.1146/annurev.immunol.18.1.767
10.1186/2051-1426-3-S2-P175
10.1002/eji.201948204
10.1080/14712598.2020.1738379
10.1016/j.immuni.2012.12.004
10.1038/ni.2714
10.4049/jimmunol.1602102
10.1016/j.immuni.2013.05.018
10.1016/j.immuni.2019.03.028
10.1038/nri2526
10.3389/fcell.2020.00233
10.1158/1078-0432.CCR-16-3133
10.1172/JCI65459
10.1021/ja209924v
10.1158/2159-8290.CD-19-1416
10.1016/j.smim.2019.101307
10.1016/j.celrep.2017.06.088
10.1038/nri2337
10.1038/s41422-020-0277-x
10.4110/in.2019.19.e32
10.1038/ncomms13353
10.1007/s12026-012-8349-8
10.1517/14712598.7.11.1705
10.1084/jem.168.4.1211
10.1038/s41467-017-00468-w
10.2147/OTT.S182806
10.1016/j.cyto.2012.06.017
10.1111/imr.12308
10.1038/s41392-020-0107-0
10.1091/mbc.e08-08-0839
10.1016/j.it.2012.10.004
10.1038/s41590-019-0405-2
10.1016/j.immuni.2009.01.008
10.1016/j.ccell.2016.10.010
10.1016/j.immuni.2011.05.013
10.1038/nm1359
10.1016/j.immuni.2009.09.022
10.1074/jbc.M604192200
10.1038/nature25015
10.1038/ni.2885
10.1016/j.immuni.2013.07.012
10.1038/srep08805
10.1084/jem.20140283
10.1371/journal.pone.0036542
10.1016/j.coi.2019.03.001
10.1038/ni.3558
10.3390/pharmaceutics12020153
10.15252/embr.202050308
10.1038/s41375-020-0949-z
10.15252/embj.201899766
10.4049/jimmunol.163.4.1775
10.3390/ijms17111829
10.15252/embj.2018100299
10.1038/ncomms14278
ContentType Journal Article
Copyright The Author(s) 2020
The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2020
– notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1038/s41392-020-00421-2
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni)
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals (DOAJ)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

CrossRef
MEDLINE
Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 2059-3635
EndPage 15
ExternalDocumentID oai_doaj_org_article_d9592e3b2b9f482e870503d222a2096c
PMC7804490
33436547
10_1038_s41392_020_00421_2
Genre Review
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas)
  grantid: RP190287
  funderid: https://doi.org/10.13039/100004917
– fundername: Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID)
  grantid: AI057555; AI064639
  funderid: https://doi.org/10.13039/100006492
– fundername: U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)
  grantid: GM84459
  funderid: https://doi.org/10.13039/100000057
– fundername: NIAID NIH HHS
  grantid: R01 AI064639
– fundername: NIAID NIH HHS
  grantid: R01 AI057555
– fundername: NIAID NIH HHS
  grantid: R37 AI064639
– fundername: ;
  grantid: GM84459
– fundername: ;
  grantid: AI057555; AI064639
– fundername: ;
  grantid: RP190287
GroupedDBID 0R~
3V.
5VS
7X7
8FI
8FJ
AAJSJ
ABUWG
ACGFS
ACSMW
ADBBV
AFKRA
AJTQC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
EBLON
EBS
EJD
EMOBN
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HYE
M7P
NAO
OK1
PIMPY
PQQKQ
PROAC
RNT
RPM
SNYQT
UKHRP
AASML
AAYXX
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7XB
8FE
8FH
8FK
AZQEC
DWQXO
GNUQQ
H94
K9.
LK8
PKEHL
PQEST
PQGLB
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c606t-55e9f3fdc85999a6ac41c93e4cb81c11b4acbba8b36089e365c919d23396d1b13
IEDL.DBID 7X7
ISSN 2059-3635
2095-9907
IngestDate Wed Aug 27 01:08:42 EDT 2025
Thu Aug 21 18:25:58 EDT 2025
Fri Jul 11 08:30:06 EDT 2025
Sat Aug 23 14:46:15 EDT 2025
Mon Jul 21 05:51:02 EDT 2025
Tue Jul 01 03:15:13 EDT 2025
Thu Apr 24 23:06:55 EDT 2025
Fri Feb 21 02:39:11 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c606t-55e9f3fdc85999a6ac41c93e4cb81c11b4acbba8b36089e365c919d23396d1b13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0001-7353-9400
0000-0002-9289-2215
OpenAccessLink https://www.proquest.com/docview/2477090424?pq-origsite=%requestingapplication%
PMID 33436547
PQID 2477090424
PQPubID 2041911
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_d9592e3b2b9f482e870503d222a2096c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7804490
proquest_miscellaneous_2477500753
proquest_journals_2477090424
pubmed_primary_33436547
crossref_primary_10_1038_s41392_020_00421_2
crossref_citationtrail_10_1038_s41392_020_00421_2
springer_journals_10_1038_s41392_020_00421_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-01-13
PublicationDateYYYYMMDD 2021-01-13
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-13
  day: 13
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Signal transduction and targeted therapy
PublicationTitleAbbrev Sig Transduct Target Ther
PublicationTitleAlternate Signal Transduct Target Ther
PublicationYear 2021
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Wang, Su, Wan (CR168) 2011; 35
Dougan (CR118) 2010; 207
Senft, Qi, Ronai (CR196) 2018; 18
Reissig (CR142) 2012; 189
Wang (CR204) 2020; 18
Chen, Sun, Chen (CR32) 2016; 17
Hershko, Ciechanover (CR4) 1998; 67
Dou (CR180) 2019; 203
Giardino Torchia (CR111) 2015; 45
Lee, Elly, Park, Liu (CR163) 2015; 42
van Loosdregt (CR165) 2013; 39
Liu (CR133) 2002; 99
Furuta, Walseng, Roche (CR40) 2013; 110
Pratama (CR114) 2013; 38
Arora (CR195) 2019; 50
Deshpande (CR132) 2013; 190
Zou (CR95) 2014; 15
Liu, Mintern, Villadangos (CR37) 2019; 58
Teague (CR134) 2006; 12
CR164
Yang (CR84) 2015; 16
Loeser (CR74) 2007; 204
Doedens (CR161) 2013; 14
Wang (CR198) 2018; 9
Yang, Sun (CR188) 2015; 266
Paolino (CR172) 2014; 507
Lyle (CR99) 2019; 9
Dang (CR152) 2011; 146
Qiao, Tang, Fu (CR33) 2017; 45
Michie (CR209) 2019; 7
Lu (CR125) 2018; 33
Xiao (CR121) 2012; 13
Stromnes (CR78) 2010; 120
Kim (CR120) 2017; 8
Huang, Marvin, Tatsis, Eisenlohr (CR15) 2011; 186
Sakaguchi (CR138) 2020; 38
Michalek (CR14) 1993; 363
Tcherpakov (CR27) 2009; 284
Chang (CR94) 2011; 12
Molfetta (CR175) 2014; 44
Lamark, Svenning, Johansen (CR127) 2017; 61
Wang (CR181) 2019; 20
Hoover, Gullickson, Kornbluth (CR179) 2009; 183
CR148
Kozlowski (CR177) 1999; 163
Adashek (CR215) 2020; 6
Azpilikueta (CR110) 2017; 7
Townsend (CR13) 1988; 168
Reinicke (CR46) 2019; 203
Tsuchida (CR54) 2010; 33
Fujiwara, Anstadt, Clark (CR76) 2017; 8
Carpino (CR86) 2004; 20
Shekhar (CR211) 2016; 7
Huang (CR203) 2019; 7
Sun (CR57) 2020; 21
Mishra, Sullivan, Caligiuri (CR131) 2014; 20
Fuertes (CR51) 2013; 34
Xiao (CR212) 2018; 7
Bartee (CR38) 2004; 78
Ackerman, Giodini, Cresswell (CR17) 2006; 25
Burr (CR200) 2017; 549
Grootjans, Kaser, Kaufman, Blumberg (CR30) 2016; 16
Jinesh, Chunduru, Kamat (CR207) 2012; 92
Chang (CR146) 2012; 13
Colbert, Cruz, Rock (CR12) 2020; 64
CR119
Giordano (CR92) 2014; 111
Zhou (CR88) 2004; 427
Liu (CR223) 2020; 10
Tze (CR44) 2011; 208
Peer, Baier, Gruber (CR77) 2017; 8
Fu, Zhu, Xu, Li (CR227) 2019; 12
De Gassart (CR42) 2008; 105
Alloatti, Kotsias, Magalhaes, Amigorena (CR10) 2016; 272
Thibodeau (CR43) 2008; 38
Blount (CR23) 2012; 7
Palazon, Goldrath, Nizet, Johnson (CR159) 2014; 41
Anandasabapathy (CR80) 2003; 18
CR19
Vetters (CR182) 2019; 216
Kim (CR186) 2017; 20
Wang (CR226) 2017; 12
McNamee, Korns Johnson, Homann, Clambey (CR160) 2013; 55
Palucka, Banchereau (CR9) 2013; 39
Gotwals (CR1) 2017; 17
Sun (CR117) 2012; 246
Cho, Walseng, Ishido, Roche (CR41) 2015; 112
Kriegel, Rathinam, Flavell (CR81) 2009; 106
CR213
Guilliams (CR8) 2014; 14
Fang (CR216) 2020; 5
Liu (CR55) 2017; 18
Li (CR166) 2016; 7
Rivera Vargas (CR126) 2017; 8
Fortier, Kornbluth (CR178) 2006; 176
Yu (CR192) 2019; 10
Chen, Mellman (CR7) 2013; 39
Triozzi (CR79) 2015; 3
Vogel (CR115) 2013; 38
Vinuesa (CR116) 2005; 435
Yang, Sun (CR96) 2018; 12
Mezzadra (CR199) 2017; 549
Calleja, Laguerre, Parker, Larijani (CR137) 2009; 7
Oh, Ghosh (CR143) 2013; 252
CR25
Crouse, Xu, Lang, Oxenius (CR170) 2015; 36
Lim (CR100) 2016; 30
Meng (CR98) 2018; 564
Zhao (CR155) 2015; 194
Chang, Jin, Sun (CR53) 2009; 10
Song (CR59) 2008; 14
Acuto, Michel (CR65) 2003; 3
Palazon (CR162) 2017; 32
Wang (CR225) 2016; 13
Wang (CR21) 2013; 191
Weiss, Subleski, Wigginton, Wiltrout (CR64) 2007; 7
Hu (CR85) 2016; 213
Fu, Lin, Zhang, Zhang (CR107) 2020; 10
Breckpot (CR60) 2009; 182
Yu (CR113) 2007; 450
Plitas, Rudensky (CR139) 2020; 4
Guo (CR112) 2019; 12
Sahin (CR217) 2020; 6
Bachmaier (CR71) 2000; 403
Zhong (CR191) 2017; 8
Ward (CR228) 2018; 293
Harhaj, Dixit (CR58) 2012; 246
Huntington, Cursons, Rautela (CR169) 2020; 20
Banchereau (CR48) 2000; 18
Kaelin (CR158) 2008; 8
Schnell, Bod, Madi, Kuchroo (CR67) 2020; 30
Lee (CR140) 2010; 285
Schauer (CR221) 2020; 10
Kim (CR174) 2010; 32
Yang (CR26) 2014; 211
Kato (CR214) 2017; 23
Sharma, Allison (CR2) 2015; 161
Temmerman (CR56) 2006; 108
Li (CR29) 2019; 10
Li, Gong, Gu (CR70) 2019; 291
Rettinger (CR208) 2014; 2
Reiley (CR89) 2007; 204
Zhong (CR31) 2009; 30
Hu, Sun (CR5) 2016; 26
Buckley (CR219) 2012; 134
Li, Liu (CR224) 2020; 191
Xiao (CR52) 2017; 214
MacKenzie (CR157) 2007; 282
Palmer (CR47) 2018; 200
Chester, Ambulkar, Kohrt (CR106) 2016; 65
Feldman, van der Goot (CR20) 2009; 19
Teh (CR150) 2016; 7
Croft (CR103) 2009; 9
Zhang (CR167) 2013; 288
Smith-Garvin, Koretzky, Jordan (CR68) 2009; 27
Zhang (CR101) 2018; 553
Venuprasad (CR145) 2008; 9
Jin (CR189) 2015; 6
Jung, Hong, Kim, Mook-Jung (CR24) 2015; 5
Knudson, Hodge, Schlom, Gameiro (CR135) 2020; 20
Harada (CR156) 2010; 207
Kool (CR61) 2011; 35
Hammer (CR62) 2011; 12
Sun (CR3) 2008; 8
Williams, Urbe (CR36) 2007; 8
Duwel (CR91) 2009; 182
Watts (CR102) 2005; 23
Kim (CR187) 2019; 19
Schwartz (CR34) 1996; 2
Qi (CR222) 2020; 8
Chang (CR147) 2014; 211
van Loosdregt (CR153) 2011; 6
Nurieva (CR82) 2010; 32
Paolino, Penninger (CR69) 2010; 32
Haymaker (CR83) 2017; 8
Schildberg, Klein, Freeman, Sharpe (CR97) 2016; 44
Joffre, Segura, Savina, Amigorena (CR11) 2012; 12
Coscoy, Ganem (CR35) 2000; 97
Chiang, Jang, Hodes, Gu (CR73) 2007; 117
Zhu (CR151) 2018; 293
Shourian, Beltra, Bourdin, Decaluwe (CR128) 2019; 42
Schauer (CR220) 2020; 63
Sun (CR87) 2004; 14
Wculek (CR6) 2020; 20
Quatrini (CR176) 2015; 8
DeNardo, Ruffell (CR183) 2019; 19
Lalani (CR190) 2015; 194
Croft (CR66) 2003; 3
Sun (CR105) 2017; 17
Deng (CR197) 2020; 5
Fang (CR218) 2019; 7
Coornaert (CR90) 2008; 9
Jin (CR63) 2016; 17
Wohlfert, Callahan, Clark (CR75) 2004; 173
Rivera Vargas (CR123) 2017; 39
Sasaki, Iwai (CR149) 2015; 266
Neurath, Kaplan (CR122) 2017; 39
Gstalder (CR205) 2020; 10
Ward-Kavanagh, Lin, Sedy, Ware (CR104) 2016; 44
Fischer (CR144) 2017; 199
Bottcher (CR171) 2018; 172
Zhou (CR136) 2019; 20
Imai (CR18) 2005; 17
Chiang (CR72) 2000; 403
Xiao (CR185) 2013; 19
Chen (CR154) 2013; 39
Liu (CR202) 2009; 174
Oh, Shin (CR39) 2015; 266
Leonard, Lin, O’Shea (CR129) 2019; 50
Ye (CR193) 2012; 287
Chirino (CR173) 2020; 50
Clancy-Thompson (CR210) 2018; 6
Lyapina (CR201) 2001; 292
Mittal, Roche (CR45) 2015; 34
Shi, Sun (CR108) 2018; 9
Martinez-Forero (CR109) 2013; 190
CR194
Long (CR50) 2009; 31
Preston, Brodsky (CR22) 2017; 474
Cassetta, Pollard (CR184) 2018; 17
Zhao (CR141) 2011; 286
Tcherpakov (CR28) 2008; 19
Castillo, Schluns (CR130) 2012; 59
Wu, Chen (CR49) 2014; 32
Verdeil, Schmitt-Verhulst (CR93) 2014; 3
Ackerman, Kyritsis, Tampe, Cresswell (CR16) 2005; 6
Lu (CR124) 2012; 122
Cossu, Milani, Mastrangelo, Lecis (CR206) 2019; 17
J Zhang (421_CR101) 2018; 553
I Sahin (421_CR217) 2020; 6
EN McNamee (421_CR160) 2013; 55
W Fang (421_CR216) 2020; 5
M Kozlowski (421_CR177) 1999; 163
XD Yang (421_CR188) 2015; 266
SJ Ward (421_CR228) 2018; 293
LE Tze (421_CR44) 2011; 208
AL Doedens (421_CR161) 2013; 14
X Meng (421_CR98) 2018; 564
S Kato (421_CR214) 2017; 23
D Kim (421_CR186) 2017; 20
D Senft (421_CR196) 2018; 18
J Zhong (421_CR191) 2017; 8
DL Buckley (421_CR219) 2012; 134
M Chang (421_CR53) 2009; 10
M Tcherpakov (421_CR27) 2009; 284
AL Ackerman (421_CR16) 2005; 6
NJ Schauer (421_CR221) 2020; 10
A Hershko (421_CR4) 1998; 67
RI Nurieva (421_CR82) 2010; 32
MT Michalek (421_CR14) 1993; 363
L Coscoy (421_CR35) 2000; 97
T Rivera Vargas (421_CR123) 2017; 39
JM Weiss (421_CR64) 2007; 7
421_CR148
S Lyapina (421_CR201) 2001; 292
E Rettinger (421_CR208) 2014; 2
FA Schildberg (421_CR97) 2016; 44
Y Lu (421_CR124) 2012; 122
J Crouse (421_CR170) 2015; 36
H Hu (421_CR5) 2016; 26
WG Kaelin Jr. (421_CR158) 2008; 8
Y Xiao (421_CR185) 2013; 19
E Clancy-Thompson (421_CR210) 2018; 6
SO Lim (421_CR100) 2016; 30
A Pratama (421_CR114) 2013; 38
Y Wang (421_CR181) 2019; 20
A Alloatti (421_CR10) 2016; 272
L Huang (421_CR15) 2011; 186
S Ye (421_CR193) 2012; 287
H Arora (421_CR195) 2019; 50
Y Guo (421_CR112) 2019; 12
RL Williams (421_CR36) 2007; 8
TH Watts (421_CR102) 2005; 23
Y Liu (421_CR202) 2009; 174
M Tcherpakov (421_CR28) 2008; 19
DA MacKenzie (421_CR157) 2007; 282
J Qiao (421_CR33) 2017; 45
SM Qi (421_CR222) 2020; 8
H Hu (421_CR85) 2016; 213
T Lamark (421_CR127) 2017; 61
JY Chiang (421_CR73) 2007; 117
L Deng (421_CR197) 2020; 5
DS Chen (421_CR7) 2013; 39
RM Teague (421_CR134) 2006; 12
K Palucka (421_CR9) 2013; 39
J Zhang (421_CR167) 2013; 288
OP Joffre (421_CR11) 2012; 12
J Michie (421_CR209) 2019; 7
421_CR119
MB Fuertes (421_CR51) 2013; 34
J Jin (421_CR189) 2015; 6
DS Kim (421_CR120) 2017; 8
G Verdeil (421_CR93) 2014; 3
EF Castillo (421_CR130) 2012; 59
J Banchereau (421_CR48) 2000; 18
A De Gassart (421_CR42) 2008; 105
MA Kriegel (421_CR81) 2009; 106
MF Neurath (421_CR122) 2017; 39
Y Dou (421_CR180) 2019; 203
SC Sun (421_CR105) 2017; 17
L Quatrini (421_CR176) 2015; 8
A Townsend (421_CR13) 1988; 168
ML Burr (421_CR200) 2017; 549
XT Song (421_CR59) 2008; 14
F Wang (421_CR226) 2017; 12
SC Sun (421_CR3) 2008; 8
JH Chang (421_CR147) 2014; 211
S Loeser (421_CR74) 2007; 204
H Oh (421_CR143) 2013; 252
M Chang (421_CR94) 2011; 12
ES Jung (421_CR24) 2015; 5
Y Harada (421_CR156) 2010; 207
JC Fischer (421_CR144) 2017; 199
K Furuta (421_CR40) 2013; 110
V Calleja (421_CR137) 2009; 7
421_CR213
JJ Adashek (421_CR215) 2020; 6
Y Wang (421_CR198) 2018; 9
Y Xiao (421_CR52) 2017; 214
Y Zhao (421_CR141) 2011; 286
T Yu (421_CR192) 2019; 10
H Wang (421_CR21) 2013; 191
S Peer (421_CR77) 2017; 8
N Carpino (421_CR86) 2004; 20
A Palazon (421_CR162) 2017; 32
C Fu (421_CR227) 2019; 12
J Wu (421_CR49) 2014; 32
JD Colbert (421_CR12) 2020; 64
M Guilliams (421_CR8) 2014; 14
RG Hoover (421_CR179) 2009; 183
Y Li (421_CR166) 2016; 7
A Palazon (421_CR159) 2014; 41
P Gotwals (421_CR1) 2017; 17
KM Knudson (421_CR135) 2020; 20
ML Giardino Torchia (421_CR111) 2015; 45
R Molfetta (421_CR175) 2014; 44
T Rivera Vargas (421_CR126) 2017; 8
L Sun (421_CR87) 2004; 14
J Thibodeau (421_CR43) 2008; 38
T Tsuchida (421_CR54) 2010; 33
R Mezzadra (421_CR199) 2017; 549
M Yang (421_CR84) 2015; 16
X Li (421_CR70) 2019; 291
TM Shekhar (421_CR211) 2016; 7
B Zhong (421_CR31) 2009; 30
ST Temmerman (421_CR56) 2006; 108
S Reissig (421_CR142) 2012; 189
M Giordano (421_CR92) 2014; 111
M Dougan (421_CR118) 2010; 207
L Cassetta (421_CR184) 2018; 17
CG Vinuesa (421_CR116) 2005; 435
DD Fang (421_CR218) 2019; 7
P Li (421_CR224) 2020; 191
EV Dang (421_CR152) 2011; 146
KJ Cho (421_CR41) 2015; 112
S Sakaguchi (421_CR138) 2020; 38
AL Palmer (421_CR47) 2018; 200
Q Zou (421_CR95) 2014; 15
EW Harhaj (421_CR58) 2012; 246
F Zhu (421_CR151) 2018; 293
G Plitas (421_CR139) 2020; 4
NJ Schauer (421_CR220) 2020; 63
O Schwartz (421_CR34) 1996; 2
P Triozzi (421_CR79) 2015; 3
M Long (421_CR50) 2009; 31
GE Hammer (421_CR62) 2011; 12
EA Wohlfert (421_CR75) 2004; 173
HS Kim (421_CR174) 2010; 32
Z Liu (421_CR223) 2020; 10
X Huang (421_CR203) 2019; 7
GM Preston (421_CR22) 2017; 474
SC Sun (421_CR117) 2012; 246
JH Chang (421_CR146) 2012; 13
LM Chirino (421_CR173) 2020; 50
ND Huntington (421_CR169) 2020; 20
X Zhou (421_CR136) 2019; 20
K Liu (421_CR133) 2002; 99
AJ Lee (421_CR140) 2010; 285
Q Chen (421_CR32) 2016; 17
O Acuto (421_CR65) 2003; 3
WJ Leonard (421_CR129) 2019; 50
IM Stromnes (421_CR78) 2010; 120
E Bartee (421_CR38) 2004; 78
AT Reinicke (421_CR46) 2019; 203
C Lyle (421_CR99) 2019; 9
K Bachmaier (421_CR71) 2000; 403
N Anandasabapathy (421_CR80) 2003; 18
D Yu (421_CR113) 2007; 450
A Schnell (421_CR67) 2020; 30
WW Reiley (421_CR89) 2007; 204
Z Chen (421_CR154) 2013; 39
P Sharma (421_CR2) 2015; 161
JE Smith-Garvin (421_CR68) 2009; 27
M Paolino (421_CR69) 2010; 32
Y Li (421_CR29) 2019; 10
M Fujiwara (421_CR76) 2017; 8
421_CR19
I Martinez-Forero (421_CR109) 2013; 190
421_CR25
H Yang (421_CR26) 2014; 211
421_CR194
JR Blount (421_CR23) 2012; 7
C Haymaker (421_CR83) 2017; 8
KU Vogel (421_CR115) 2013; 38
L Wang (421_CR225) 2016; 13
LK Ward-Kavanagh (421_CR104) 2016; 44
H Zhou (421_CR88) 2004; 427
K Venuprasad (421_CR145) 2008; 9
Y Fu (421_CR107) 2020; 10
SC Sun (421_CR57) 2020; 21
M Shourian (421_CR128) 2019; 42
X Xiao (421_CR121) 2012; 13
M Paolino (421_CR172) 2014; 507
K Sasaki (421_CR149) 2015; 266
Y Wang (421_CR168) 2011; 35
Y Wang (421_CR204) 2020; 18
B Coornaert (421_CR90) 2008; 9
Y Lu (421_CR125) 2018; 33
J van Loosdregt (421_CR165) 2013; 39
J Jin (421_CR63) 2016; 17
SK Wculek (421_CR6) 2020; 20
J Oh (421_CR39) 2015; 266
JP Bottcher (421_CR171) 2018; 172
C Chester (421_CR106) 2016; 65
DG DeNardo (421_CR183) 2019; 19
M Duwel (421_CR91) 2009; 182
D Kim (421_CR187) 2019; 19
J van Loosdregt (421_CR153) 2011; 6
JH Lee (421_CR163) 2015; 42
M Croft (421_CR66) 2003; 3
JM Fortier (421_CR178) 2006; 176
JH Shi (421_CR108) 2018; 9
H Liu (421_CR37) 2019; 58
GG Jinesh (421_CR207) 2012; 92
R Xiao (421_CR212) 2018; 7
B Liu (421_CR55) 2017; 18
XD Yang (421_CR96) 2018; 12
M Feldman (421_CR20) 2009; 19
A Azpilikueta (421_CR110) 2017; 7
J Vetters (421_CR182) 2019; 216
AL Ackerman (421_CR17) 2006; 25
YJ Chiang (421_CR72) 2000; 403
J Grootjans (421_CR30) 2016; 16
F Cossu (421_CR206) 2019; 17
A Mishra (421_CR131) 2014; 20
CE Teh (421_CR150) 2016; 7
M Kool (421_CR61) 2011; 35
AI Lalani (421_CR190) 2015; 194
Y Zhao (421_CR155) 2015; 194
SK Mittal (421_CR45) 2015; 34
421_CR164
C Gstalder (421_CR205) 2020; 10
J Imai (421_CR18) 2005; 17
K Breckpot (421_CR60) 2009; 182
P Deshpande (421_CR132) 2013; 190
M Croft (421_CR103) 2009; 9
References_xml – volume: 44
  start-page: 2761
  year: 2014
  end-page: 2770
  ident: CR175
  article-title: c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.201444512
– volume: 7
  year: 2016
  ident: CR166
  article-title: USP21 prevents the generation of T-helper-1-like Treg cells
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms13559
– volume: 8
  start-page: 41841
  year: 2017
  end-page: 41853
  ident: CR77
  article-title: Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.18360
– volume: 288
  start-page: 9373
  year: 2013
  end-page: 9382
  ident: CR167
  article-title: Identification of the E3 deubiquitinase ubiquitin-specific peptidase 21 (USP21) as a positive regulator of the transcription factor GATA3
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M112.374744
– volume: 2
  start-page: 338
  year: 1996
  end-page: 342
  ident: CR34
  article-title: Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein
  publication-title: Nat. Med.
  doi: 10.1038/nm0396-338
– volume: 182
  start-page: 860
  year: 2009
  end-page: 870
  ident: CR60
  article-title: Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.182.2.860
– volume: 17
  start-page: 286
  year: 2017
  end-page: 301
  ident: CR1
  article-title: Prospects for combining targeted and conventional cancer therapy with immunotherapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2017.17
– volume: 19
  start-page: 595
  year: 2013
  end-page: 602
  ident: CR185
  article-title: Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation
  publication-title: Nat. Med.
  doi: 10.1038/nm.3111
– volume: 507
  start-page: 508
  year: 2014
  end-page: 512
  ident: CR172
  article-title: The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
  publication-title: Nature
  doi: 10.1038/nature12998
– volume: 92
  start-page: 233
  year: 2012
  end-page: 244
  ident: CR207
  article-title: Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-alpha but not through TRAIL and FasL
  publication-title: J. Leukoc. Biol.
  doi: 10.1189/jlb.1211623
– volume: 12
  year: 2017
  ident: CR226
  article-title: Active site-targeted covalent irreversible inhibitors of USP7 impair the functions of Foxp3+ T-regulatory cells by promoting ubiquitination of Tip60
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0189744
– volume: 200
  start-page: 928
  year: 2018
  end-page: 936
  ident: CR47
  article-title: Inhibition of the deubiquitinase Usp14 diminishes direct MHC class I antigen presentation
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1700273
– volume: 172
  start-page: 1022
  year: 2018
  end-page: 1037 e1014
  ident: CR171
  article-title: NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control
  publication-title: Cell
  doi: 10.1016/j.cell.2018.01.004
– volume: 17
  start-page: 259
  year: 2016
  end-page: 268
  ident: CR63
  article-title: Epigenetic regulation of the expression of Il12 and Il23 and autoimmune inflammation by the deubiquitinase Trabid
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.3347
– volume: 38
  start-page: 1225
  year: 2008
  end-page: 1230
  ident: CR43
  article-title: Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.200737902
– volume: 7
  start-page: 183
  year: 2019
  end-page: 192
  ident: CR209
  article-title: Antagonism of IAPs enhances CAR T-cell efficacy. Cancer
  publication-title: Immunol. Res
– volume: 110
  start-page: 20188
  year: 2013
  end-page: 20193
  ident: CR40
  article-title: Internalizing MHC class II-peptide complexes are ubiquitinated in early endosomes and targeted for lysosomal degradation
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1312994110
– volume: 12
  start-page: 451
  year: 2018
  end-page: 462
  ident: CR96
  article-title: Deubiquitinases as pivotal regulators of T cell functions
  publication-title: Front. Med.
  doi: 10.1007/s11684-018-0651-y
– volume: 16
  start-page: 1253
  year: 2015
  end-page: 1262
  ident: CR84
  article-title: K33-linked polyubiquitination of Zap70 by Nrdp1 controls CD8(+) T cell activation
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.3258
– volume: 9
  start-page: 245
  year: 2008
  end-page: 253
  ident: CR145
  article-title: The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1
  publication-title: Nat. Immunol.
  doi: 10.1038/ni1564
– volume: 6
  year: 2011
  ident: CR153
  article-title: Rapid temporal control of Foxp3 protein degradation by sirtuin-1
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0019047
– volume: 403
  start-page: 216
  year: 2000
  end-page: 220
  ident: CR72
  article-title: Cbl-b regualtes the CD28 dependence of T-cell activation
  publication-title: Nature
  doi: 10.1038/35003235
– volume: 17
  start-page: 142
  year: 2019
  end-page: 150
  ident: CR206
  article-title: Targeting the BIR domains of inhibitor of apoptosis (IAP) proteins in cancer treatment
  publication-title: Comput. Struct. Biotechnol. J.
  doi: 10.1016/j.csbj.2019.01.009
– volume: 10
  year: 2020
  ident: CR221
  article-title: Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-62076-x
– volume: 8
  year: 2017
  ident: CR120
  article-title: Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-017-00324-x
– volume: 21
  start-page: 362
  year: 2020
  end-page: 364
  ident: CR57
  article-title: A20 restricts inflammation via ubiquitin binding
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-020-0632-6
– volume: 12
  start-page: 1184
  year: 2011
  end-page: 1193
  ident: CR62
  article-title: Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2135
– volume: 7
  year: 2009
  ident: CR137
  article-title: Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition
  publication-title: PLoS Biol.
  doi: 10.1371/journal.pbio.1000017
– volume: 182
  start-page: 7718
  year: 2009
  end-page: 7728
  ident: CR91
  article-title: A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0803313
– volume: 5
  year: 2020
  ident: CR216
  article-title: MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
  publication-title: ESMO Open
  doi: 10.1136/esmoopen-2019-000614
– ident: CR213
– volume: 18
  start-page: 214
  year: 2017
  end-page: 224
  ident: CR55
  article-title: The ubiquitin E3 ligase TRIM31 promotes aggregation and activation of the signaling adaptor MAVS through Lys63-linked polyubiquitination
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.3641
– volume: 7
  start-page: 33866
  year: 2016
  end-page: 33886
  ident: CR211
  article-title: IAP antagonists sensitize murine osteosarcoma cells to killing by TNFalpha
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.8980
– volume: 108
  start-page: 2324
  year: 2006
  end-page: 2331
  ident: CR56
  article-title: Impaired dendritic-cell function in ectodermal dysplasia with immune deficiency is linked to defective NEMO ubiquitination
  publication-title: Blood
  doi: 10.1182/blood-2006-04-017210
– volume: 36
  start-page: 49
  year: 2015
  end-page: 58
  ident: CR170
  article-title: NK cells regulating T cell responses: mechanisms and outcome
  publication-title: Trends Immunol.
  doi: 10.1016/j.it.2014.11.001
– volume: 7
  start-page: 327
  year: 2019
  ident: CR218
  article-title: MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-019-0750-6
– volume: 291
  start-page: 123
  year: 2019
  end-page: 133
  ident: CR70
  article-title: Regulation of immune system development and function by Cbl-mediated ubiquitination
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12789
– volume: 8
  year: 2017
  ident: CR191
  article-title: Ubiquitylation of MFHAS1 by the ubiquitin ligase praja2 promotes M1 macrophage polarization by activating JNK and p38 pathways
  publication-title: Cell Death Dis.
  doi: 10.1038/cddis.2017.102
– volume: 207
  start-page: 2195
  year: 2010
  end-page: 2206
  ident: CR118
  article-title: IAP inhibitors enhance co-stimulation to promote tumor immunity
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20101123
– volume: 20
  start-page: 7
  year: 2020
  end-page: 24
  ident: CR6
  article-title: Dendritic cells in cancer immunology and immunotherapy
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-019-0210-z
– volume: 7
  year: 2017
  ident: CR110
  article-title: Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB)
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2017.1368605
– volume: 4
  start-page: 459
  year: 2020
  end-page: 477
  ident: CR139
  article-title: Regulatory T cells in cancer
  publication-title: Annu. Rev. Cancer Biol.
  doi: 10.1146/annurev-cancerbio-030419-033428
– volume: 564
  start-page: 130
  year: 2018
  end-page: 135
  ident: CR98
  article-title: FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells
  publication-title: Nature
  doi: 10.1038/s41586-018-0756-0
– volume: 287
  start-page: 26740
  year: 2012
  end-page: 26748
  ident: CR193
  article-title: The E3 ubiquitin ligase neuregulin receptor degradation protein 1 (Nrdp1) promotes M2 macrophage polarization by ubiquitinating and activating transcription factor CCAAT/enhancer-binding Protein beta (C/EBPbeta)
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M112.383265
– volume: 6
  start-page: 57
  year: 2020
  ident: CR217
  article-title: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
  publication-title: Cell Death Discov.
  doi: 10.1038/s41420-020-0292-1
– volume: 266
  start-page: 134
  year: 2015
  end-page: 144
  ident: CR39
  article-title: Molecular mechanism and cellular function of MHCII ubiquitination
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12303
– volume: 7
  year: 2018
  ident: CR212
  article-title: Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1471440
– volume: 32
  start-page: 670
  year: 2010
  end-page: 680
  ident: CR82
  article-title: The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation
  publication-title: Immunity
  doi: 10.1016/j.immuni.2010.05.002
– volume: 207
  start-page: 1381
  year: 2010
  end-page: 1391
  ident: CR156
  article-title: Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20100004
– volume: 67
  start-page: 425
  year: 1998
  end-page: 479
  ident: CR4
  article-title: The ubiquitin system
  publication-title: Annu. Rev. Biochem.
  doi: 10.1146/annurev.biochem.67.1.425
– volume: 191
  start-page: 6010
  year: 2013
  end-page: 6021
  ident: CR21
  article-title: Enhanced endoplasmic reticulum entry of tumor antigen is crucial for cross-presentation induced by dendritic cell-targeted vaccination
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1302312
– volume: 61
  start-page: 609
  year: 2017
  end-page: 624
  ident: CR127
  article-title: Regulation of selective autophagy: the p62/SQSTM1 paradigm
  publication-title: Essays Biochem.
  doi: 10.1042/EBC20170035
– volume: 176
  start-page: 6454
  year: 2006
  end-page: 6463
  ident: CR178
  article-title: NK lytic-associated molecule, involved in NK cytotoxic function, is an E3 ligase
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.176.11.6454
– volume: 33
  start-page: 1048
  year: 2018
  end-page: 1060.e1047
  ident: CR125
  article-title: Th9 cells represent a unique subset of CD4(+) T cells endowed with the ability to eradicate advanced tumors
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.05.004
– volume: 203
  start-page: 873
  year: 2019
  end-page: 880
  ident: CR180
  article-title: Identification of the E3 ligase TRIM29 as a critical checkpoint regulator of NK cell functions
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1900171
– volume: 194
  start-page: 334
  year: 2015
  end-page: 348
  ident: CR190
  article-title: Myeloid cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1401548
– volume: 27
  start-page: 591
  year: 2009
  end-page: 619
  ident: CR68
  article-title: T cell activation
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev.immunol.021908.132706
– volume: 191
  start-page: 112107
  year: 2020
  ident: CR224
  article-title: Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors
  publication-title: Eur. J. Med Chem.
  doi: 10.1016/j.ejmech.2020.112107
– volume: 252
  start-page: 41
  year: 2013
  end-page: 51
  ident: CR143
  article-title: NF-kappaB: roles and regulation in different CD4(+) T-cell subsets
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12033
– volume: 8
  year: 2017
  ident: CR83
  article-title: Absence of Grail promotes CD8(+) T cell anti-tumour activity
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-017-00252-w
– volume: 2
  start-page: 75
  year: 2014
  ident: CR208
  article-title: SMAC mimetic BV6 enables sensitization of resistant tumor cells but also affects cytokine-induced killer (CIK) cells: a potential challenge for combination therapy
  publication-title: Front. Pediatr.
  doi: 10.3389/fped.2014.00075
– ident: CR148
– volume: 120
  start-page: 3722
  year: 2010
  end-page: 3734
  ident: CR78
  article-title: Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI41991
– volume: 163
  start-page: 1775
  year: 1999
  end-page: 1785
  ident: CR177
  article-title: NK lytic-associated molecule: a novel gene selectively expressed in cells with cytolytic function
  publication-title: J. Immunol.
– volume: 8
  start-page: 42
  year: 2017
  ident: CR76
  article-title: Cbl-b deficiency mediates resistance to programmed death-ligand 1/programmed death-1 regulation
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2017.00042
– volume: 25
  start-page: 607
  year: 2006
  end-page: 617
  ident: CR17
  article-title: A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells
  publication-title: Immunity
  doi: 10.1016/j.immuni.2006.08.017
– volume: 8
  start-page: 355
  year: 2007
  end-page: 368
  ident: CR36
  article-title: The emerging shape of the ESCRT machinery
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/nrm2162
– volume: 9
  start-page: 263
  year: 2008
  end-page: A271
  ident: CR90
  article-title: T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20
  publication-title: Nat. Immunol.
  doi: 10.1038/ni1561
– volume: 9
  year: 2019
  ident: CR99
  article-title: c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-019-56208-1
– volume: 292
  start-page: 1382
  year: 2001
  end-page: 1385
  ident: CR201
  article-title: Promotion of NEDD-CUL1 conjugate cleavage by COP9 signalosome
  publication-title: Science
  doi: 10.1126/science.1059780
– volume: 17
  start-page: 45
  year: 2005
  end-page: 53
  ident: CR18
  article-title: Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells
  publication-title: Int. Immunol.
  doi: 10.1093/intimm/dxh184
– volume: 16
  start-page: 469
  year: 2016
  end-page: 484
  ident: CR30
  article-title: The unfolded protein response in immunity and inflammation
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri.2016.62
– volume: 20
  start-page: 37
  year: 2004
  end-page: 46
  ident: CR86
  article-title: Regulation of ZAP-70 activation and TCR signaling by two related proteins Sts-1 Sts-2
  publication-title: Immunity
  doi: 10.1016/S1074-7613(03)00351-0
– volume: 111
  start-page: 11115
  year: 2014
  end-page: 11120
  ident: CR92
  article-title: The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1406259111
– volume: 266
  start-page: 56
  year: 2015
  end-page: 71
  ident: CR188
  article-title: Targeting signaling factors for degradation, an emerging mechanism for TRAF functions
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12311
– volume: 7
  start-page: 1580
  year: 2019
  end-page: 1590
  ident: CR203
  article-title: USP22 deubiquitinates CD274 to suppress anticancer immunity. Cancer
  publication-title: Immunol. Res
– volume: 8
  start-page: 865
  year: 2008
  end-page: 873
  ident: CR158
  article-title: The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2502
– volume: 204
  start-page: 879
  year: 2007
  end-page: 891
  ident: CR74
  article-title: Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20061699
– volume: 44
  start-page: 1005
  year: 2016
  end-page: 1019
  ident: CR104
  article-title: The TNF receptor superfamily in co-stimulating and co-inhibitory responses
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.04.019
– volume: 435
  start-page: 452
  year: 2005
  end-page: 458
  ident: CR116
  article-title: A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity
  publication-title: Nature
  doi: 10.1038/nature03555
– volume: 32
  start-page: 175
  year: 2010
  end-page: 186
  ident: CR174
  article-title: Synergistic signals for natural cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase
  publication-title: Immunity
  doi: 10.1016/j.immuni.2010.02.004
– volume: 10
  year: 2019
  ident: CR192
  article-title: Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-12384-2
– volume: 6
  year: 2015
  ident: CR189
  article-title: Proinflammatory TLR signalling is regulated by a TRAF2-dependent proteolysis mechanism in macrophages
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms6930
– volume: 6
  start-page: 181
  year: 2020
  end-page: 191
  ident: CR215
  article-title: Hyperprogression and immunotherapy: fact, fiction, or alternative fact? Trends
  publication-title: Cancer
– volume: 6
  start-page: 107
  year: 2005
  end-page: 113
  ident: CR16
  article-title: Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells
  publication-title: Nat. Immunol.
  doi: 10.1038/ni1147
– volume: 32
  start-page: 669
  year: 2017
  end-page: 683.e665
  ident: CR162
  article-title: An HIF-1alpha/VEGF-A axis in cytotoxic T cells regulates tumor progression
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.10.003
– volume: 293
  start-page: 17362
  year: 2018
  end-page: 17374
  ident: CR228
  article-title: The structure of the deubiquitinase USP15 reveals a misaligned catalytic triad and an open ubiquitin-binding channel
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA118.003857
– volume: 10
  year: 2019
  ident: CR29
  article-title: Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5(-/-) mice
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-09525-y
– volume: 213
  start-page: 399
  year: 2016
  end-page: 414
  ident: CR85
  article-title: Otud7b facilitates T cell activation and inflammatory responses by regulating Zap70 ubiquitination
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20151426
– volume: 284
  start-page: 12099
  year: 2009
  end-page: 12109
  ident: CR27
  article-title: Regulation of endoplasmic reticulum-associated degradation by RNF5-dependent ubiquitination of JNK-associated membrane protein (JAMP)
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M808222200
– volume: 106
  start-page: 16770
  year: 2009
  end-page: 16775
  ident: CR81
  article-title: E3 ubiquitin ligase GRAIL controls primary T cell activation and oral tolerance
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.0908957106
– volume: 3
  start-page: 609
  year: 2003
  end-page: 620
  ident: CR66
  article-title: Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri1148
– volume: 183
  start-page: 6913
  year: 2009
  end-page: 6921
  ident: CR179
  article-title: Impaired NK cytolytic activity and enhanced tumor growth in NK lytic-associated molecule-deficient mice
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0901679
– volume: 216
  start-page: 2010
  year: 2019
  end-page: 2023
  ident: CR182
  article-title: The ubiquitin-editing enzyme A20 controls NK cell homeostasis through regulation of mTOR activity and TNF
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20182164
– volume: 78
  start-page: 1109
  year: 2004
  end-page: 1120
  ident: CR38
  article-title: Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins
  publication-title: J. Virol.
  doi: 10.1128/JVI.78.3.1109-1120.2004
– volume: 32
  start-page: 137
  year: 2010
  end-page: 148
  ident: CR69
  article-title: Cbl-b in T-cell activation
  publication-title: Semin. Immunopathol.
  doi: 10.1007/s00281-010-0197-9
– volume: 105
  start-page: 3491
  year: 2008
  end-page: 3496
  ident: CR42
  article-title: MHC class II stabilization at the surface of human dendritic cells is the result of maturation-dependent MARCH I down-regulation
  publication-title: Proc. Natl Acad. Sci. USA.
  doi: 10.1073/pnas.0708874105
– volume: 18
  start-page: 535
  year: 2003
  end-page: 547
  ident: CR80
  article-title: GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells
  publication-title: Immunity
  doi: 10.1016/S1074-7613(03)00084-0
– volume: 427
  start-page: 167
  year: 2004
  end-page: 171
  ident: CR88
  article-title: Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO
  publication-title: Nature
  doi: 10.1038/nature02273
– volume: 8
  start-page: ra108
  year: 2015
  ident: CR176
  article-title: Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells
  publication-title: Sci. Signal.
  doi: 10.1126/scisignal.aab2724
– volume: 549
  start-page: 106
  year: 2017
  end-page: 110
  ident: CR199
  article-title: Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
  publication-title: Nature
  doi: 10.1038/nature23669
– ident: CR194
– volume: 13
  start-page: 481
  year: 2012
  end-page: 490
  ident: CR146
  article-title: Ubc13 maintains the suppressive function of regulatory T cells and prevents their conversion into effector-like T cells
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2267
– volume: 17
  start-page: 887
  year: 2018
  end-page: 904
  ident: CR184
  article-title: Targeting macrophages: therapeutic approaches in cancer
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd.2018.169
– volume: 13
  start-page: 99
  year: 2016
  end-page: 112
  ident: CR225
  article-title: Ubiquitin-specific protease-7 inhibition impairs Tip60-dependent Foxp3+ T-regulatory cell function and promotes antitumor immunity
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2016.10.018
– volume: 33
  start-page: 765
  year: 2010
  end-page: 776
  ident: CR54
  article-title: The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA
  publication-title: Immunity
  doi: 10.1016/j.immuni.2010.10.013
– volume: 3
  start-page: 939
  year: 2003
  end-page: 951
  ident: CR65
  article-title: CD28-mediated co-stimulation: a quantitative support for TCR signalling
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri1248
– volume: 174
  start-page: 1415
  year: 2009
  end-page: 1425
  ident: CR202
  article-title: COP9-associated CSN5 regulates exosomal protein deubiquitination and sorting
  publication-title: Am. J. Pathol.
  doi: 10.2353/ajpath.2009.080861
– volume: 26
  start-page: 457
  year: 2016
  end-page: 483
  ident: CR5
  article-title: Ubiquitin signaling in immune responses
  publication-title: Cell Res.
  doi: 10.1038/cr.2016.40
– volume: 38
  start-page: 669
  year: 2013
  end-page: 680
  ident: CR114
  article-title: Roquin-2 shares functions with its paralog Roquin-1 in the repression of mRNAs controlling T follicular helper cells and systemic inflammation
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.01.011
– volume: 161
  start-page: 205
  year: 2015
  end-page: 214
  ident: CR2
  article-title: Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
  publication-title: Cell
  doi: 10.1016/j.cell.2015.03.030
– volume: 19
  start-page: 357
  year: 2009
  end-page: 363
  ident: CR20
  article-title: Novel ubiquitin-dependent quality control in the endoplasmic reticulum
  publication-title: Trends Cell Biol.
  doi: 10.1016/j.tcb.2009.05.005
– volume: 246
  start-page: 107
  year: 2012
  end-page: 124
  ident: CR58
  article-title: Regulation of NF-kappaB by deubiquitinases
  publication-title: Immunol. Rev.
  doi: 10.1111/j.1600-065X.2012.01100.x
– volume: 23
  start-page: 23
  year: 2005
  end-page: 68
  ident: CR102
  article-title: Tnf/Tnfr family members in costimulation of T cell responses
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev.immunol.23.021704.115839
– volume: 34
  start-page: 22
  year: 2015
  end-page: 27
  ident: CR45
  article-title: Suppression of antigen presentation by IL-10
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2014.12.009
– volume: 285
  start-page: 15696
  year: 2010
  end-page: 15703
  ident: CR140
  article-title: CARMA1 regulation of regulatory T cell development involves modulation of interleukin-2 receptor signaling
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M109.095190
– volume: 63
  start-page: 2731
  year: 2020
  end-page: 2750
  ident: CR220
  article-title: Advances in discovering deubiquitinating enzyme (DUB) inhibitors
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.9b01138
– volume: 10
  start-page: 414
  year: 2020
  end-page: 433
  ident: CR107
  article-title: Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2019.08.010
– volume: 194
  start-page: 1639
  year: 2015
  end-page: 1645
  ident: CR155
  article-title: E3 ubiquitin ligase Cbl-b regulates thymic-derived CD4+CD25+ regulatory T cell development by targeting Foxp3 for ubiquitination
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1402434
– volume: 65
  start-page: 1243
  year: 2016
  end-page: 1248
  ident: CR106
  article-title: 4-1BB agonism: adding the accelerator to cancer immunotherapy
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-016-1829-2
– volume: 14
  start-page: 258
  year: 2008
  end-page: 265
  ident: CR59
  article-title: A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression
  publication-title: Nat. Med.
  doi: 10.1038/nm1721
– volume: 50
  start-page: 418
  year: 2019
  end-page: 431.e416
  ident: CR195
  article-title: The ATP-binding cassette gene ABCF1 functions as an E2 ubiquitin-conjugating enzyme controlling Macrophage polarization to dampen lethal septic shock
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.01.014
– volume: 17
  start-page: 545
  year: 2017
  end-page: 558
  ident: CR105
  article-title: The non-canonical NF-kappaB pathway in immunity and inflammation
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri.2017.52
– volume: 246
  start-page: 125
  year: 2012
  end-page: 140
  ident: CR117
  article-title: The noncanonical NF-kappaB pathway
  publication-title: Immunol. Rev.
  doi: 10.1111/j.1600-065X.2011.01088.x
– volume: 20
  start-page: 2044
  year: 2014
  end-page: 2050
  ident: CR131
  article-title: Molecular pathways: interleukin-15 signaling in health and in cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-3603
– volume: 186
  start-page: 1904
  year: 2011
  end-page: 1908
  ident: CR15
  article-title: Cutting Edge: selective role of ubiquitin in MHC class I antigen presentation
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1003411
– volume: 20
  start-page: 10
  year: 2019
  end-page: 17
  ident: CR181
  article-title: The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-018-0265-1
– volume: 363
  start-page: 552
  year: 1993
  end-page: 554
  ident: CR14
  article-title: A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation
  publication-title: Nature
  doi: 10.1038/363552a0
– volume: 32
  start-page: 461
  year: 2014
  end-page: 488
  ident: CR49
  article-title: Innate immune sensing and signaling of cytosolic nucleic acids
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev-immunol-032713-120156
– volume: 13
  start-page: 981
  year: 2012
  end-page: 990
  ident: CR121
  article-title: OX40 signaling favors the induction of T(H)9 cells and airway inflammation
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2390
– volume: 450
  start-page: 299
  year: 2007
  end-page: 303
  ident: CR113
  article-title: Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA
  publication-title: Nature
  doi: 10.1038/nature06253
– ident: CR25
– volume: 42
  start-page: 1062
  year: 2015
  end-page: 1074
  ident: CR163
  article-title: E3 ubiquitin ligase VHL regulates hypoxia-inducible factor-1alpha to maintain regulatory T cell stability and suppressive capacity
  publication-title: Immunity
  doi: 10.1016/j.immuni.2015.05.016
– volume: 474
  start-page: 445
  year: 2017
  end-page: 469
  ident: CR22
  article-title: The evolving role of ubiquitin modification in endoplasmic reticulum-associated degradation
  publication-title: Biochem. J.
  doi: 10.1042/BCJ20160582
– volume: 208
  start-page: 149
  year: 2011
  end-page: 165
  ident: CR44
  article-title: CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20092203
– volume: 9
  start-page: 1849
  year: 2018
  ident: CR108
  article-title: Tumor necrosis factor receptor-associated factor regulation of nuclear factor kappaB and mitogen-activated protein kinase pathways
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.01849
– volume: 99
  start-page: 6192
  year: 2002
  end-page: 6197
  ident: CR133
  article-title: IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T cells
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.092675799
– volume: 14
  start-page: 289
  year: 2004
  end-page: 301
  ident: CR87
  article-title: The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes
  publication-title: Mol. Cell.
  doi: 10.1016/S1097-2765(04)00236-9
– volume: 189
  start-page: 4770
  year: 2012
  end-page: 4776
  ident: CR142
  article-title: The tumor suppressor CYLD controls the function of murine regulatory T cells
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1201993
– ident: CR19
– volume: 10
  start-page: 1476
  year: 2020
  end-page: 1491
  ident: CR223
  article-title: Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as highly potent, selective, and cellularly active USP28 inhibitors
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2019.12.008
– volume: 146
  start-page: 772
  year: 2011
  end-page: 784
  ident: CR152
  article-title: Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1
  publication-title: Cell
  doi: 10.1016/j.cell.2011.07.033
– volume: 203
  start-page: 1730
  year: 2019
  end-page: 1742
  ident: CR46
  article-title: Deubiquitinating enzyme UCH-L1 promotes dendritic cell antigen cross-presentation by favoring recycling of MHC class I molecules
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1801133
– volume: 38
  start-page: 541
  year: 2020
  end-page: 566
  ident: CR138
  article-title: Regulatory T cells and human disease
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev-immunol-042718-041717
– volume: 173
  start-page: 1059
  year: 2004
  end-page: 1065
  ident: CR75
  article-title: Resistance to CD4+CD25+ regulatory T cells and TGF-beta in Cbl-b-/- mice
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.173.2.1059
– volume: 10
  start-page: 1089
  year: 2009
  end-page: 1095
  ident: CR53
  article-title: Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.1777
– volume: 39
  start-page: 1
  year: 2017
  end-page: 4
  ident: CR122
  article-title: Th9 cells in immunity and immunopathological diseases
  publication-title: Semin Immunopathol.
  doi: 10.1007/s00281-016-0611-z
– volume: 112
  start-page: 10449
  year: 2015
  end-page: 10454
  ident: CR41
  article-title: Ubiquitination by March-I prevents MHC class II recycling and promotes MHC class II turnover in antigen-presenting cells
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1507981112
– volume: 272
  start-page: 97
  year: 2016
  end-page: 108
  ident: CR10
  article-title: Dendritic cell maturation and cross-presentation: timing matters!
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12432
– volume: 190
  start-page: 1416
  year: 2013
  end-page: 1423
  ident: CR132
  article-title: IL-7- and IL-15-mediated TCR sensitization enables T cell responses to self-antigens
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1201620
– volume: 403
  start-page: 211
  year: 2000
  end-page: 216
  ident: CR71
  article-title: Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b
  publication-title: Nature
  doi: 10.1038/35003228
– ident: CR164
– volume: 549
  start-page: 101
  year: 2017
  end-page: 105
  ident: CR200
  article-title: CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
  publication-title: Nature
  doi: 10.1038/nature23643
– volume: 190
  start-page: 6694
  year: 2013
  end-page: 6706
  ident: CR109
  article-title: T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1203010
– volume: 117
  start-page: 1029
  year: 2007
  end-page: 1036
  ident: CR73
  article-title: Ablation of Cbl-b provides protection against transplanted and spontaneous tumors
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI29472
– volume: 293
  start-page: 20099
  year: 2018
  end-page: 20111
  ident: CR151
  article-title: Ring finger protein 31-mediated atypical ubiquitination stabilizes forkhead box P3 and thereby stimulates regulatory T-cell function
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA118.005802
– volume: 18
  year: 2020
  ident: CR204
  article-title: The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells
  publication-title: Cell Commun. Signal
  doi: 10.1186/s12964-020-00612-y
– volume: 14
  start-page: 571
  year: 2014
  end-page: 578
  ident: CR8
  article-title: Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3712
– volume: 39
  start-page: 39
  year: 2017
  end-page: 46
  ident: CR123
  article-title: TH9 cells in anti-tumor immunity
  publication-title: Semin. Immunopathol.
  doi: 10.1007/s00281-016-0599-4
– volume: 12
  start-page: 557
  year: 2012
  end-page: 569
  ident: CR11
  article-title: Cross-presentation by dendritic cells
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3254
– volume: 12
  start-page: 10629
  year: 2019
  end-page: 10637
  ident: CR112
  article-title: NEDD4 negatively regulates GITR via ubiquitination in immune microenvironment of melanoma
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S212317
– volume: 45
  start-page: 16
  year: 2017
  end-page: 20
  ident: CR33
  article-title: DNA sensing and immune responses in cancer therapy
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2016.12.005
– volume: 18
  start-page: 69
  year: 2018
  end-page: 88
  ident: CR196
  article-title: Ubiquitin ligases in oncogenic transformation and cancer therapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2017.105
– volume: 20
  start-page: 437
  year: 2020
  end-page: 454
  ident: CR169
  article-title: The cancer-natural killer cell immunity cycle
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-020-0272-z
– volume: 12
  start-page: 1002
  year: 2011
  end-page: 1009
  ident: CR94
  article-title: The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2090
– volume: 41
  start-page: 518
  year: 2014
  end-page: 528
  ident: CR159
  article-title: HIF transcription factors, inflammation, and immunity
  publication-title: Immunity
  doi: 10.1016/j.immuni.2014.09.008
– volume: 19
  start-page: 369
  year: 2019
  end-page: 382
  ident: CR183
  article-title: Macrophages as regulators of tumour immunity and immunotherapy
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-019-0127-6
– volume: 44
  start-page: 955
  year: 2016
  end-page: 972
  ident: CR97
  article-title: Coinhibitory pathways in the B7-CD28 ligand-receptor family
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.05.002
– volume: 97
  start-page: 8051
  year: 2000
  end-page: 8056
  ident: CR35
  article-title: Kaposi’s sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.140129797
– volume: 45
  start-page: 2672
  year: 2015
  end-page: 2682
  ident: CR111
  article-title: c-IAP ubiquitin protein ligase activity is required for 4-1BB signaling and CD8(+) memory T-cell survival
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.201445342
– volume: 211
  start-page: 137
  year: 2014
  end-page: 151
  ident: CR147
  article-title: TRAF3 regulates the effector function of regulatory T cells and humoral immune responses
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20131019
– volume: 39
  start-page: 272
  year: 2013
  end-page: 285
  ident: CR154
  article-title: The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.08.006
– volume: 64
  start-page: 1
  year: 2020
  end-page: 8
  ident: CR12
  article-title: Cross-presentation of exogenous antigens on MHC I molecules
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2019.12.005
– volume: 39
  start-page: 38
  year: 2013
  end-page: 48
  ident: CR9
  article-title: Dendritic-cell-based therapeutic cancer vaccines
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.07.004
– volume: 286
  start-page: 40520
  year: 2011
  end-page: 40530
  ident: CR141
  article-title: The deubiquitinase CYLD targets Smad7 protein to regulate transforming growth factor beta (TGF-beta) signaling and the development of regulatory T cells
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M111.292961
– ident: CR119
– volume: 35
  start-page: 337
  year: 2011
  end-page: 348
  ident: CR168
  article-title: An essential role of the transcription factor GATA-3 for the function of regulatory T cells
  publication-title: Immunity
  doi: 10.1016/j.immuni.2011.08.012
– volume: 204
  start-page: 1475
  year: 2007
  end-page: 1485
  ident: CR89
  article-title: Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20062694
– volume: 9
  start-page: 536
  year: 2018
  ident: CR198
  article-title: Regulation of PD-L1: emerging routes for targeting tumor immune evasion
  publication-title: Front. Pharm.
  doi: 10.3389/fphar.2018.00536
– volume: 214
  start-page: 1493
  year: 2017
  end-page: 1507
  ident: CR52
  article-title: The kinase TBK1 functions in dendritic cells to regulate T cell homeostasis, autoimmunity, and antitumor immunity
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20161524
– volume: 3
  year: 2014
  ident: CR93
  article-title: Unleashing antitumor T-cell activation without ensuing autoimmunity: the case for A20-deletion in adoptive CD8(+) T-cell therapy
  publication-title: Oncoimmunology
  doi: 10.4161/21624011.2014.958951
– volume: 18
  start-page: 767
  year: 2000
  end-page: 811
  ident: CR48
  article-title: Immunobiology of dendritic cells
  publication-title: Annu Rev. Immunol.
  doi: 10.1146/annurev.immunol.18.1.767
– volume: 3
  start-page: 175
  year: 2015
  ident: CR79
  article-title: Phase I clinical trial of adoptive cellular immunotherapy with APN401 in patients with solid tumors
  publication-title: J. Immunother. Cancer
  doi: 10.1186/2051-1426-3-S2-P175
– volume: 50
  start-page: 48
  year: 2020
  end-page: 55
  ident: CR173
  article-title: TAM receptors attenuate murine NK-cell responses via E3 ubiquitin ligase Cbl-b
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.201948204
– volume: 20
  start-page: 705
  year: 2020
  end-page: 709
  ident: CR135
  article-title: Rationale for IL-15 superagonists in cancer immunotherapy
  publication-title: Expert Opin. Biol. Ther.
  doi: 10.1080/14712598.2020.1738379
– volume: 38
  start-page: 655
  year: 2013
  end-page: 668
  ident: CR115
  article-title: Roquin paralogs 1 and 2 redundantly repress the Icos and Ox40 costimulator mRNAs and control follicular helper T cell differentiation
  publication-title: Immunity
  doi: 10.1016/j.immuni.2012.12.004
– volume: 14
  start-page: 1173
  year: 2013
  end-page: 1182
  ident: CR161
  article-title: Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2714
– volume: 199
  start-page: 2356
  year: 2017
  end-page: 2365
  ident: CR144
  article-title: A20 restrains thymic regulatory T cell development
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1602102
– volume: 39
  start-page: 259
  year: 2013
  end-page: 271
  ident: CR165
  article-title: Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.05.018
– volume: 50
  start-page: 832
  year: 2019
  end-page: 850
  ident: CR129
  article-title: The gammac family of cytokines: basic biology to therapeutic ramifications
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.03.028
– volume: 9
  start-page: 271
  year: 2009
  end-page: 285
  ident: CR103
  article-title: The role of TNF superfamily members in T-cell function and diseases
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri2526
– volume: 8
  start-page: 233
  year: 2020
  ident: CR222
  article-title: Targeting USP7-mediated deubiquitination of MDM2/MDMX-p53 pathway for cancer therapy: are we there yet?
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2020.00233
– volume: 23
  start-page: 4242
  year: 2017
  end-page: 4250
  ident: CR214
  article-title: Hyperprogressors after Immunotherapy: analysis of genomic alterations associated with accelerated growth rate
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-3133
– volume: 122
  start-page: 4160
  year: 2012
  end-page: 4171
  ident: CR124
  article-title: Th9 cells promote antitumor immune responses in vivo
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI65459
– volume: 134
  start-page: 4465
  year: 2012
  end-page: 4468
  ident: CR219
  article-title: Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1alpha interaction
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/ja209924v
– volume: 10
  start-page: 1296
  year: 2020
  end-page: 1311
  ident: CR205
  article-title: Inactivation of Fbxw7 Impairs dsRNA sensing and confers resistance to PD-1 blockade
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-19-1416
– volume: 42
  start-page: 101307
  year: 2019
  ident: CR128
  article-title: Common gamma chain cytokines and CD8 T cells in cancer
  publication-title: Semin. Immunol.
  doi: 10.1016/j.smim.2019.101307
– volume: 20
  start-page: 832
  year: 2017
  end-page: 845
  ident: CR186
  article-title: Cytosolic Pellino-1-mediated K63-linked ubiquitination of IRF5 in M1 macrophages regulates glucose intolerance in obesity
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2017.06.088
– volume: 8
  start-page: 501
  year: 2008
  end-page: 511
  ident: CR3
  article-title: Deubiquitylation and regulation of the immune response
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri2337
– volume: 30
  start-page: 285
  year: 2020
  end-page: 299
  ident: CR67
  article-title: The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
  publication-title: Cell Res.
  doi: 10.1038/s41422-020-0277-x
– volume: 19
  year: 2019
  ident: CR187
  article-title: Ubiquitin E3 ligase pellino-1 inhibits IL-10-mediated M2c polarization of macrophages, thereby suppressing tumor growth
  publication-title: Immune Netw.
  doi: 10.4110/in.2019.19.e32
– volume: 6
  start-page: 25
  year: 2018
  end-page: 35
  ident: CR210
  article-title: IAP antagonists enhance cytokine production from mouse and human iNKT cells. Cancer
  publication-title: Immunol. Res.
– volume: 7
  year: 2016
  ident: CR150
  article-title: Linear ubiquitin chain assembly complex coordinates late thymic T-cell differentiation and regulatory T-cell homeostasis
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms13353
– volume: 55
  start-page: 58
  year: 2013
  end-page: 70
  ident: CR160
  article-title: Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function
  publication-title: Immunol. Res.
  doi: 10.1007/s12026-012-8349-8
– volume: 7
  start-page: 1705
  year: 2007
  end-page: 1721
  ident: CR64
  article-title: Immunotherapy of cancer by IL-12-based cytokine combinations
  publication-title: Expert Opin. Biol. Ther.
  doi: 10.1517/14712598.7.11.1705
– volume: 168
  start-page: 1211
  year: 1988
  end-page: 1224
  ident: CR13
  article-title: Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.168.4.1211
– volume: 8
  year: 2017
  ident: CR126
  article-title: Selective degradation of PU.1 during autophagy represses the differentiation and antitumour activity of TH9 cells
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-017-00468-w
– volume: 12
  start-page: 609
  year: 2019
  end-page: 617
  ident: CR227
  article-title: Pharmacological inhibition of USP7 promotes antitumor immunity and contributes to colon cancer therapy
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S182806
– volume: 59
  start-page: 479
  year: 2012
  end-page: 490
  ident: CR130
  article-title: Regulating the immune system via IL-15 transpresentation
  publication-title: Cytokine
  doi: 10.1016/j.cyto.2012.06.017
– volume: 266
  start-page: 175
  year: 2015
  end-page: 189
  ident: CR149
  article-title: Roles of linear ubiquitinylation, a crucial regulator of NF-kappaB and cell death, in the immune system
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12308
– volume: 5
  start-page: 11
  year: 2020
  ident: CR197
  article-title: The role of ubiquitination in tumorigenesis and targeted drug discovery
  publication-title: Signal Transduct. Target Ther.
  doi: 10.1038/s41392-020-0107-0
– volume: 19
  start-page: 5019
  year: 2008
  end-page: 5028
  ident: CR28
  article-title: JAMP optimizes ERAD to protect cells from unfolded proteins
  publication-title: Mol. Biol. Cell
  doi: 10.1091/mbc.e08-08-0839
– volume: 34
  start-page: 67
  year: 2013
  end-page: 73
  ident: CR51
  article-title: Type I interferon response and innate immune sensing of cancer
  publication-title: Trends Immunol.
  doi: 10.1016/j.it.2012.10.004
– volume: 20
  start-page: 879
  year: 2019
  end-page: 889
  ident: CR136
  article-title: The deubiquitinase Otub1 controls the activation of CD8(+) T cells and NK cells by regulating IL-15-mediated priming
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-019-0405-2
– volume: 30
  start-page: 397
  year: 2009
  end-page: 407
  ident: CR31
  article-title: The ubiquitin ligase RNF5 regulates antiviral responses by mediating degradation of the adaptor protein MITA
  publication-title: Immunity
  doi: 10.1016/j.immuni.2009.01.008
– volume: 30
  start-page: 925
  year: 2016
  end-page: 939
  ident: CR100
  article-title: Deubiquitination and Stabilization of PD-L1 by CSN5
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.10.010
– volume: 35
  start-page: 82
  year: 2011
  end-page: 96
  ident: CR61
  article-title: The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity
  publication-title: Immunity
  doi: 10.1016/j.immuni.2011.05.013
– volume: 12
  start-page: 335
  year: 2006
  end-page: 341
  ident: CR134
  article-title: Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors
  publication-title: Nat. Med.
  doi: 10.1038/nm1359
– volume: 31
  start-page: 921
  year: 2009
  end-page: 931
  ident: CR50
  article-title: Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor
  publication-title: Immunity
  doi: 10.1016/j.immuni.2009.09.022
– volume: 282
  start-page: 9696
  year: 2007
  end-page: 9702
  ident: CR157
  article-title: GRAIL is up-regulated in CD4+ CD25+ T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M604192200
– volume: 553
  start-page: 91
  year: 2018
  end-page: 95
  ident: CR101
  article-title: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
  publication-title: Nature
  doi: 10.1038/nature25015
– volume: 15
  start-page: 562
  year: 2014
  end-page: 570
  ident: CR95
  article-title: USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2885
– volume: 39
  start-page: 1
  year: 2013
  end-page: 10
  ident: CR7
  article-title: Oncology meets immunology: the cancer-immunity cycle
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.07.012
– volume: 5
  year: 2015
  ident: CR24
  article-title: Acute ER stress regulates amyloid precursor protein processing through ubiquitin-dependent degradation
  publication-title: Sci. Rep.
  doi: 10.1038/srep08805
– volume: 211
  start-page: 2467
  year: 2014
  end-page: 2479
  ident: CR26
  article-title: Hrd1-mediated BLIMP-1 ubiquitination promotes dendritic cell MHCII expression for CD4 T cell priming during inflammation
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20140283
– volume: 7
  year: 2012
  ident: CR23
  article-title: Ubiquitin-specific protease 25 functions in endoplasmic reticulum-associated degradation
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0036542
– volume: 58
  start-page: 38
  year: 2019
  end-page: 43
  ident: CR37
  article-title: MARCH ligases in immunity
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2019.03.001
– volume: 17
  start-page: 1142
  year: 2016
  end-page: 1149
  ident: CR32
  article-title: Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.3558
– volume: 9
  start-page: 245
  year: 2008
  ident: 421_CR145
  publication-title: Nat. Immunol.
  doi: 10.1038/ni1564
– volume: 7
  year: 2009
  ident: 421_CR137
  publication-title: PLoS Biol.
  doi: 10.1371/journal.pbio.1000017
– volume: 3
  start-page: 175
  year: 2015
  ident: 421_CR79
  publication-title: J. Immunother. Cancer
  doi: 10.1186/2051-1426-3-S2-P175
– volume: 161
  start-page: 205
  year: 2015
  ident: 421_CR2
  publication-title: Cell
  doi: 10.1016/j.cell.2015.03.030
– volume: 10
  year: 2019
  ident: 421_CR192
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-12384-2
– volume: 191
  start-page: 6010
  year: 2013
  ident: 421_CR21
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1302312
– volume: 39
  start-page: 1
  year: 2017
  ident: 421_CR122
  publication-title: Semin Immunopathol.
  doi: 10.1007/s00281-016-0611-z
– volume: 39
  start-page: 259
  year: 2013
  ident: 421_CR165
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.05.018
– volume: 31
  start-page: 921
  year: 2009
  ident: 421_CR50
  publication-title: Immunity
  doi: 10.1016/j.immuni.2009.09.022
– volume: 173
  start-page: 1059
  year: 2004
  ident: 421_CR75
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.173.2.1059
– volume: 7
  year: 2016
  ident: 421_CR166
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms13559
– volume: 39
  start-page: 272
  year: 2013
  ident: 421_CR154
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.08.006
– volume: 403
  start-page: 211
  year: 2000
  ident: 421_CR71
  publication-title: Nature
  doi: 10.1038/35003228
– volume: 266
  start-page: 56
  year: 2015
  ident: 421_CR188
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12311
– volume: 78
  start-page: 1109
  year: 2004
  ident: 421_CR38
  publication-title: J. Virol.
  doi: 10.1128/JVI.78.3.1109-1120.2004
– volume: 2
  start-page: 75
  year: 2014
  ident: 421_CR208
  publication-title: Front. Pediatr.
  doi: 10.3389/fped.2014.00075
– volume: 208
  start-page: 149
  year: 2011
  ident: 421_CR44
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20092203
– volume: 7
  year: 2016
  ident: 421_CR150
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms13353
– volume: 41
  start-page: 518
  year: 2014
  ident: 421_CR159
  publication-title: Immunity
  doi: 10.1016/j.immuni.2014.09.008
– volume: 6
  start-page: 107
  year: 2005
  ident: 421_CR16
  publication-title: Nat. Immunol.
  doi: 10.1038/ni1147
– volume: 2
  start-page: 338
  year: 1996
  ident: 421_CR34
  publication-title: Nat. Med.
  doi: 10.1038/nm0396-338
– volume: 14
  start-page: 258
  year: 2008
  ident: 421_CR59
  publication-title: Nat. Med.
  doi: 10.1038/nm1721
– volume: 10
  year: 2020
  ident: 421_CR221
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-62076-x
– volume: 211
  start-page: 2467
  year: 2014
  ident: 421_CR26
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20140283
– volume: 25
  start-page: 607
  year: 2006
  ident: 421_CR17
  publication-title: Immunity
  doi: 10.1016/j.immuni.2006.08.017
– volume: 9
  start-page: 263
  year: 2008
  ident: 421_CR90
  publication-title: Nat. Immunol.
  doi: 10.1038/ni1561
– volume: 288
  start-page: 9373
  year: 2013
  ident: 421_CR167
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M112.374744
– volume: 122
  start-page: 4160
  year: 2012
  ident: 421_CR124
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI65459
– volume: 3
  start-page: 939
  year: 2003
  ident: 421_CR65
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri1248
– volume: 106
  start-page: 16770
  year: 2009
  ident: 421_CR81
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.0908957106
– ident: 421_CR19
  doi: 10.3390/pharmaceutics12020153
– volume: 8
  start-page: 501
  year: 2008
  ident: 421_CR3
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri2337
– volume: 20
  start-page: 879
  year: 2019
  ident: 421_CR136
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-019-0405-2
– volume: 23
  start-page: 23
  year: 2005
  ident: 421_CR102
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev.immunol.23.021704.115839
– volume: 12
  year: 2017
  ident: 421_CR226
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0189744
– volume: 8
  start-page: ra108
  year: 2015
  ident: 421_CR176
  publication-title: Sci. Signal.
  doi: 10.1126/scisignal.aab2724
– volume: 3
  year: 2014
  ident: 421_CR93
  publication-title: Oncoimmunology
  doi: 10.4161/21624011.2014.958951
– volume: 36
  start-page: 49
  year: 2015
  ident: 421_CR170
  publication-title: Trends Immunol.
  doi: 10.1016/j.it.2014.11.001
– volume: 182
  start-page: 860
  year: 2009
  ident: 421_CR60
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.182.2.860
– volume: 6
  year: 2015
  ident: 421_CR189
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms6930
– volume: 61
  start-page: 609
  year: 2017
  ident: 421_CR127
  publication-title: Essays Biochem.
  doi: 10.1042/EBC20170035
– volume: 14
  start-page: 289
  year: 2004
  ident: 421_CR87
  publication-title: Mol. Cell.
  doi: 10.1016/S1097-2765(04)00236-9
– volume: 207
  start-page: 2195
  year: 2010
  ident: 421_CR118
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20101123
– volume: 33
  start-page: 1048
  year: 2018
  ident: 421_CR125
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.05.004
– volume: 65
  start-page: 1243
  year: 2016
  ident: 421_CR106
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-016-1829-2
– volume: 17
  start-page: 142
  year: 2019
  ident: 421_CR206
  publication-title: Comput. Struct. Biotechnol. J.
  doi: 10.1016/j.csbj.2019.01.009
– volume: 13
  start-page: 981
  year: 2012
  ident: 421_CR121
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2390
– volume: 17
  start-page: 887
  year: 2018
  ident: 421_CR184
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd.2018.169
– volume: 33
  start-page: 765
  year: 2010
  ident: 421_CR54
  publication-title: Immunity
  doi: 10.1016/j.immuni.2010.10.013
– volume: 7
  start-page: 183
  year: 2019
  ident: 421_CR209
  publication-title: Immunol. Res
– ident: 421_CR164
  doi: 10.15252/embr.202050308
– ident: 421_CR213
  doi: 10.1038/s41375-020-0949-z
– volume: 10
  start-page: 1089
  year: 2009
  ident: 421_CR53
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.1777
– volume: 204
  start-page: 879
  year: 2007
  ident: 421_CR74
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20061699
– volume: 363
  start-page: 552
  year: 1993
  ident: 421_CR14
  publication-title: Nature
  doi: 10.1038/363552a0
– volume: 12
  start-page: 1184
  year: 2011
  ident: 421_CR62
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2135
– volume: 30
  start-page: 285
  year: 2020
  ident: 421_CR67
  publication-title: Cell Res.
  doi: 10.1038/s41422-020-0277-x
– volume: 7
  start-page: 1705
  year: 2007
  ident: 421_CR64
  publication-title: Expert Opin. Biol. Ther.
  doi: 10.1517/14712598.7.11.1705
– volume: 50
  start-page: 832
  year: 2019
  ident: 421_CR129
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.03.028
– volume: 17
  start-page: 259
  year: 2016
  ident: 421_CR63
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.3347
– volume: 19
  start-page: 595
  year: 2013
  ident: 421_CR185
  publication-title: Nat. Med.
  doi: 10.1038/nm.3111
– volume: 112
  start-page: 10449
  year: 2015
  ident: 421_CR41
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1507981112
– volume: 204
  start-page: 1475
  year: 2007
  ident: 421_CR89
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20062694
– volume: 211
  start-page: 137
  year: 2014
  ident: 421_CR147
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20131019
– volume: 8
  start-page: 41841
  year: 2017
  ident: 421_CR77
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.18360
– volume: 266
  start-page: 175
  year: 2015
  ident: 421_CR149
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12308
– volume: 18
  start-page: 69
  year: 2018
  ident: 421_CR196
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2017.105
– volume: 293
  start-page: 17362
  year: 2018
  ident: 421_CR228
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA118.003857
– volume: 8
  start-page: 865
  year: 2008
  ident: 421_CR158
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2502
– volume: 39
  start-page: 1
  year: 2013
  ident: 421_CR7
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.07.012
– volume: 99
  start-page: 6192
  year: 2002
  ident: 421_CR133
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.092675799
– volume: 20
  start-page: 2044
  year: 2014
  ident: 421_CR131
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-3603
– volume: 207
  start-page: 1381
  year: 2010
  ident: 421_CR156
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20100004
– volume: 134
  start-page: 4465
  year: 2012
  ident: 421_CR219
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/ja209924v
– volume: 168
  start-page: 1211
  year: 1988
  ident: 421_CR13
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.168.4.1211
– volume: 32
  start-page: 669
  year: 2017
  ident: 421_CR162
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.10.003
– volume: 6
  start-page: 57
  year: 2020
  ident: 421_CR217
  publication-title: Cell Death Discov.
  doi: 10.1038/s41420-020-0292-1
– volume: 8
  year: 2017
  ident: 421_CR126
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-017-00468-w
– volume: 20
  start-page: 705
  year: 2020
  ident: 421_CR135
  publication-title: Expert Opin. Biol. Ther.
  doi: 10.1080/14712598.2020.1738379
– volume: 9
  year: 2019
  ident: 421_CR99
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-019-56208-1
– ident: 421_CR148
  doi: 10.15252/embj.201899766
– volume: 16
  start-page: 1253
  year: 2015
  ident: 421_CR84
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.3258
– volume: 203
  start-page: 873
  year: 2019
  ident: 421_CR180
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1900171
– volume: 59
  start-page: 479
  year: 2012
  ident: 421_CR130
  publication-title: Cytokine
  doi: 10.1016/j.cyto.2012.06.017
– volume: 6
  start-page: 25
  year: 2018
  ident: 421_CR210
  publication-title: Immunol. Res.
– volume: 67
  start-page: 425
  year: 1998
  ident: 421_CR4
  publication-title: Annu. Rev. Biochem.
  doi: 10.1146/annurev.biochem.67.1.425
– volume: 10
  start-page: 414
  year: 2020
  ident: 421_CR107
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2019.08.010
– volume: 117
  start-page: 1029
  year: 2007
  ident: 421_CR73
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI29472
– volume: 92
  start-page: 233
  year: 2012
  ident: 421_CR207
  publication-title: J. Leukoc. Biol.
  doi: 10.1189/jlb.1211623
– volume: 45
  start-page: 16
  year: 2017
  ident: 421_CR33
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2016.12.005
– volume: 3
  start-page: 609
  year: 2003
  ident: 421_CR66
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri1148
– volume: 120
  start-page: 3722
  year: 2010
  ident: 421_CR78
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI41991
– volume: 12
  start-page: 557
  year: 2012
  ident: 421_CR11
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3254
– volume: 38
  start-page: 655
  year: 2013
  ident: 421_CR115
  publication-title: Immunity
  doi: 10.1016/j.immuni.2012.12.004
– volume: 30
  start-page: 397
  year: 2009
  ident: 421_CR31
  publication-title: Immunity
  doi: 10.1016/j.immuni.2009.01.008
– volume: 9
  start-page: 536
  year: 2018
  ident: 421_CR198
  publication-title: Front. Pharm.
  doi: 10.3389/fphar.2018.00536
– volume: 5
  start-page: 11
  year: 2020
  ident: 421_CR197
  publication-title: Signal Transduct. Target Ther.
  doi: 10.1038/s41392-020-0107-0
– volume: 44
  start-page: 2761
  year: 2014
  ident: 421_CR175
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.201444512
– volume: 26
  start-page: 457
  year: 2016
  ident: 421_CR5
  publication-title: Cell Res.
  doi: 10.1038/cr.2016.40
– volume: 27
  start-page: 591
  year: 2009
  ident: 421_CR68
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev.immunol.021908.132706
– volume: 176
  start-page: 6454
  year: 2006
  ident: 421_CR178
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.176.11.6454
– volume: 39
  start-page: 39
  year: 2017
  ident: 421_CR123
  publication-title: Semin. Immunopathol.
  doi: 10.1007/s00281-016-0599-4
– volume: 63
  start-page: 2731
  year: 2020
  ident: 421_CR220
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.9b01138
– volume: 42
  start-page: 101307
  year: 2019
  ident: 421_CR128
  publication-title: Semin. Immunol.
  doi: 10.1016/j.smim.2019.101307
– volume: 435
  start-page: 452
  year: 2005
  ident: 421_CR116
  publication-title: Nature
  doi: 10.1038/nature03555
– volume: 19
  start-page: 369
  year: 2019
  ident: 421_CR183
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-019-0127-6
– volume: 10
  start-page: 1296
  year: 2020
  ident: 421_CR205
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-19-1416
– volume: 4
  start-page: 459
  year: 2020
  ident: 421_CR139
  publication-title: Annu. Rev. Cancer Biol.
  doi: 10.1146/annurev-cancerbio-030419-033428
– volume: 7
  year: 2018
  ident: 421_CR212
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1471440
– volume: 50
  start-page: 48
  year: 2020
  ident: 421_CR173
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.201948204
– volume: 108
  start-page: 2324
  year: 2006
  ident: 421_CR56
  publication-title: Blood
  doi: 10.1182/blood-2006-04-017210
– volume: 163
  start-page: 1775
  year: 1999
  ident: 421_CR177
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.163.4.1775
– volume: 174
  start-page: 1415
  year: 2009
  ident: 421_CR202
  publication-title: Am. J. Pathol.
  doi: 10.2353/ajpath.2009.080861
– volume: 35
  start-page: 337
  year: 2011
  ident: 421_CR168
  publication-title: Immunity
  doi: 10.1016/j.immuni.2011.08.012
– volume: 200
  start-page: 928
  year: 2018
  ident: 421_CR47
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1700273
– volume: 45
  start-page: 2672
  year: 2015
  ident: 421_CR111
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.201445342
– volume: 32
  start-page: 175
  year: 2010
  ident: 421_CR174
  publication-title: Immunity
  doi: 10.1016/j.immuni.2010.02.004
– volume: 216
  start-page: 2010
  year: 2019
  ident: 421_CR182
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20182164
– volume: 58
  start-page: 38
  year: 2019
  ident: 421_CR37
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2019.03.001
– volume: 12
  start-page: 1002
  year: 2011
  ident: 421_CR94
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2090
– volume: 111
  start-page: 11115
  year: 2014
  ident: 421_CR92
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1406259111
– volume: 39
  start-page: 38
  year: 2013
  ident: 421_CR9
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.07.004
– volume: 474
  start-page: 445
  year: 2017
  ident: 421_CR22
  publication-title: Biochem. J.
  doi: 10.1042/BCJ20160582
– volume: 8
  start-page: 355
  year: 2007
  ident: 421_CR36
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/nrm2162
– volume: 20
  start-page: 10
  year: 2019
  ident: 421_CR181
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-018-0265-1
– volume: 564
  start-page: 130
  year: 2018
  ident: 421_CR98
  publication-title: Nature
  doi: 10.1038/s41586-018-0756-0
– volume: 18
  start-page: 214
  year: 2017
  ident: 421_CR55
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.3641
– volume: 7
  year: 2017
  ident: 421_CR110
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2017.1368605
– volume: 17
  start-page: 545
  year: 2017
  ident: 421_CR105
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri.2017.52
– volume: 194
  start-page: 334
  year: 2015
  ident: 421_CR190
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1401548
– volume: 403
  start-page: 216
  year: 2000
  ident: 421_CR72
  publication-title: Nature
  doi: 10.1038/35003235
– volume: 20
  start-page: 7
  year: 2020
  ident: 421_CR6
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-019-0210-z
– volume: 8
  start-page: 233
  year: 2020
  ident: 421_CR222
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2020.00233
– volume: 12
  start-page: 451
  year: 2018
  ident: 421_CR96
  publication-title: Front. Med.
  doi: 10.1007/s11684-018-0651-y
– volume: 50
  start-page: 418
  year: 2019
  ident: 421_CR195
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.01.014
– volume: 19
  start-page: 5019
  year: 2008
  ident: 421_CR28
  publication-title: Mol. Biol. Cell
  doi: 10.1091/mbc.e08-08-0839
– volume: 14
  start-page: 571
  year: 2014
  ident: 421_CR8
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3712
– volume: 12
  start-page: 335
  year: 2006
  ident: 421_CR134
  publication-title: Nat. Med.
  doi: 10.1038/nm1359
– volume: 287
  start-page: 26740
  year: 2012
  ident: 421_CR193
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M112.383265
– volume: 203
  start-page: 1730
  year: 2019
  ident: 421_CR46
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1801133
– volume: 9
  start-page: 1849
  year: 2018
  ident: 421_CR108
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.01849
– volume: 44
  start-page: 955
  year: 2016
  ident: 421_CR97
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.05.002
– volume: 190
  start-page: 6694
  year: 2013
  ident: 421_CR109
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1203010
– volume: 7
  start-page: 327
  year: 2019
  ident: 421_CR218
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-019-0750-6
– volume: 16
  start-page: 469
  year: 2016
  ident: 421_CR30
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri.2016.62
– volume: 64
  start-page: 1
  year: 2020
  ident: 421_CR12
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2019.12.005
– volume: 292
  start-page: 1382
  year: 2001
  ident: 421_CR201
  publication-title: Science
  doi: 10.1126/science.1059780
– volume: 213
  start-page: 399
  year: 2016
  ident: 421_CR85
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20151426
– volume: 14
  start-page: 1173
  year: 2013
  ident: 421_CR161
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2714
– volume: 190
  start-page: 1416
  year: 2013
  ident: 421_CR132
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1201620
– volume: 291
  start-page: 123
  year: 2019
  ident: 421_CR70
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12789
– volume: 266
  start-page: 134
  year: 2015
  ident: 421_CR39
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12303
– volume: 17
  start-page: 45
  year: 2005
  ident: 421_CR18
  publication-title: Int. Immunol.
  doi: 10.1093/intimm/dxh184
– volume: 17
  start-page: 1142
  year: 2016
  ident: 421_CR32
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.3558
– volume: 32
  start-page: 670
  year: 2010
  ident: 421_CR82
  publication-title: Immunity
  doi: 10.1016/j.immuni.2010.05.002
– volume: 110
  start-page: 20188
  year: 2013
  ident: 421_CR40
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1312994110
– volume: 507
  start-page: 508
  year: 2014
  ident: 421_CR172
  publication-title: Nature
  doi: 10.1038/nature12998
– ident: 421_CR25
  doi: 10.3390/ijms17111829
– volume: 194
  start-page: 1639
  year: 2015
  ident: 421_CR155
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1402434
– volume: 182
  start-page: 7718
  year: 2009
  ident: 421_CR91
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0803313
– volume: 18
  year: 2020
  ident: 421_CR204
  publication-title: Cell Commun. Signal
  doi: 10.1186/s12964-020-00612-y
– volume: 38
  start-page: 1225
  year: 2008
  ident: 421_CR43
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.200737902
– volume: 34
  start-page: 67
  year: 2013
  ident: 421_CR51
  publication-title: Trends Immunol.
  doi: 10.1016/j.it.2012.10.004
– volume: 186
  start-page: 1904
  year: 2011
  ident: 421_CR15
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1003411
– volume: 32
  start-page: 461
  year: 2014
  ident: 421_CR49
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev-immunol-032713-120156
– volume: 6
  year: 2011
  ident: 421_CR153
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0019047
– volume: 13
  start-page: 99
  year: 2016
  ident: 421_CR225
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2016.10.018
– volume: 42
  start-page: 1062
  year: 2015
  ident: 421_CR163
  publication-title: Immunity
  doi: 10.1016/j.immuni.2015.05.016
– volume: 12
  start-page: 10629
  year: 2019
  ident: 421_CR112
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S212317
– volume: 7
  start-page: 1580
  year: 2019
  ident: 421_CR203
  publication-title: Immunol. Res
– volume: 183
  start-page: 6913
  year: 2009
  ident: 421_CR179
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0901679
– volume: 44
  start-page: 1005
  year: 2016
  ident: 421_CR104
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.04.019
– volume: 282
  start-page: 9696
  year: 2007
  ident: 421_CR157
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M604192200
– volume: 12
  start-page: 609
  year: 2019
  ident: 421_CR227
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S182806
– volume: 8
  year: 2017
  ident: 421_CR120
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-017-00324-x
– volume: 30
  start-page: 925
  year: 2016
  ident: 421_CR100
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.10.010
– volume: 252
  start-page: 41
  year: 2013
  ident: 421_CR143
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12033
– volume: 272
  start-page: 97
  year: 2016
  ident: 421_CR10
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12432
– volume: 450
  start-page: 299
  year: 2007
  ident: 421_CR113
  publication-title: Nature
  doi: 10.1038/nature06253
– volume: 146
  start-page: 772
  year: 2011
  ident: 421_CR152
  publication-title: Cell
  doi: 10.1016/j.cell.2011.07.033
– volume: 8
  year: 2017
  ident: 421_CR83
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-017-00252-w
– volume: 21
  start-page: 362
  year: 2020
  ident: 421_CR57
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-020-0632-6
– volume: 8
  year: 2017
  ident: 421_CR191
  publication-title: Cell Death Dis.
  doi: 10.1038/cddis.2017.102
– volume: 214
  start-page: 1493
  year: 2017
  ident: 421_CR52
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20161524
– volume: 10
  year: 2019
  ident: 421_CR29
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-09525-y
– volume: 32
  start-page: 137
  year: 2010
  ident: 421_CR69
  publication-title: Semin. Immunopathol.
  doi: 10.1007/s00281-010-0197-9
– volume: 7
  year: 2012
  ident: 421_CR23
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0036542
– volume: 38
  start-page: 541
  year: 2020
  ident: 421_CR138
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev-immunol-042718-041717
– volume: 427
  start-page: 167
  year: 2004
  ident: 421_CR88
  publication-title: Nature
  doi: 10.1038/nature02273
– volume: 6
  start-page: 181
  year: 2020
  ident: 421_CR215
  publication-title: Cancer
– volume: 20
  start-page: 37
  year: 2004
  ident: 421_CR86
  publication-title: Immunity
  doi: 10.1016/S1074-7613(03)00351-0
– volume: 285
  start-page: 15696
  year: 2010
  ident: 421_CR140
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M109.095190
– volume: 284
  start-page: 12099
  year: 2009
  ident: 421_CR27
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M808222200
– volume: 23
  start-page: 4242
  year: 2017
  ident: 421_CR214
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-3133
– volume: 35
  start-page: 82
  year: 2011
  ident: 421_CR61
  publication-title: Immunity
  doi: 10.1016/j.immuni.2011.05.013
– volume: 172
  start-page: 1022
  year: 2018
  ident: 421_CR171
  publication-title: Cell
  doi: 10.1016/j.cell.2018.01.004
– volume: 191
  start-page: 112107
  year: 2020
  ident: 421_CR224
  publication-title: Eur. J. Med Chem.
  doi: 10.1016/j.ejmech.2020.112107
– volume: 105
  start-page: 3491
  year: 2008
  ident: 421_CR42
  publication-title: Proc. Natl Acad. Sci. USA.
  doi: 10.1073/pnas.0708874105
– volume: 18
  start-page: 535
  year: 2003
  ident: 421_CR80
  publication-title: Immunity
  doi: 10.1016/S1074-7613(03)00084-0
– volume: 286
  start-page: 40520
  year: 2011
  ident: 421_CR141
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M111.292961
– volume: 199
  start-page: 2356
  year: 2017
  ident: 421_CR144
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1602102
– volume: 38
  start-page: 669
  year: 2013
  ident: 421_CR114
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.01.011
– ident: 421_CR194
  doi: 10.15252/embj.2018100299
– volume: 34
  start-page: 22
  year: 2015
  ident: 421_CR45
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2014.12.009
– volume: 55
  start-page: 58
  year: 2013
  ident: 421_CR160
  publication-title: Immunol. Res.
  doi: 10.1007/s12026-012-8349-8
– volume: 20
  start-page: 437
  year: 2020
  ident: 421_CR169
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-020-0272-z
– volume: 19
  start-page: 357
  year: 2009
  ident: 421_CR20
  publication-title: Trends Cell Biol.
  doi: 10.1016/j.tcb.2009.05.005
– volume: 8
  start-page: 42
  year: 2017
  ident: 421_CR76
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2017.00042
– volume: 293
  start-page: 20099
  year: 2018
  ident: 421_CR151
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA118.005802
– volume: 10
  start-page: 1476
  year: 2020
  ident: 421_CR223
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2019.12.008
– volume: 5
  year: 2015
  ident: 421_CR24
  publication-title: Sci. Rep.
  doi: 10.1038/srep08805
– ident: 421_CR119
  doi: 10.1038/ncomms14278
– volume: 5
  year: 2020
  ident: 421_CR216
  publication-title: ESMO Open
  doi: 10.1136/esmoopen-2019-000614
– volume: 189
  start-page: 4770
  year: 2012
  ident: 421_CR142
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1201993
– volume: 246
  start-page: 107
  year: 2012
  ident: 421_CR58
  publication-title: Immunol. Rev.
  doi: 10.1111/j.1600-065X.2012.01100.x
– volume: 18
  start-page: 767
  year: 2000
  ident: 421_CR48
  publication-title: Annu Rev. Immunol.
  doi: 10.1146/annurev.immunol.18.1.767
– volume: 15
  start-page: 562
  year: 2014
  ident: 421_CR95
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2885
– volume: 13
  start-page: 481
  year: 2012
  ident: 421_CR146
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2267
– volume: 549
  start-page: 101
  year: 2017
  ident: 421_CR200
  publication-title: Nature
  doi: 10.1038/nature23643
– volume: 17
  start-page: 286
  year: 2017
  ident: 421_CR1
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2017.17
– volume: 97
  start-page: 8051
  year: 2000
  ident: 421_CR35
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.140129797
– volume: 20
  start-page: 832
  year: 2017
  ident: 421_CR186
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2017.06.088
– volume: 549
  start-page: 106
  year: 2017
  ident: 421_CR199
  publication-title: Nature
  doi: 10.1038/nature23669
– volume: 7
  start-page: 33866
  year: 2016
  ident: 421_CR211
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.8980
– volume: 553
  start-page: 91
  year: 2018
  ident: 421_CR101
  publication-title: Nature
  doi: 10.1038/nature25015
– volume: 9
  start-page: 271
  year: 2009
  ident: 421_CR103
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri2526
– volume: 246
  start-page: 125
  year: 2012
  ident: 421_CR117
  publication-title: Immunol. Rev.
  doi: 10.1111/j.1600-065X.2011.01088.x
– volume: 19
  year: 2019
  ident: 421_CR187
  publication-title: Immune Netw.
  doi: 10.4110/in.2019.19.e32
SSID ssj0001637754
ssib046561479
ssib044760960
Score 2.422241
SecondaryResourceType review_article
Snippet Cancer immunotherapy has become an attractive approach of cancer treatment with tremendous success in treating various advanced malignancies. The development...
Abstract Cancer immunotherapy has become an attractive approach of cancer treatment with tremendous success in treating various advanced malignancies. The...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 16
SubjectTerms 631/250/251
631/250/580
Cancer
Cancer Research
Cell Biology
Deubiquitinating Enzymes - immunology
Humans
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy
Internal Medicine
Medicine
Medicine & Public Health
Neoplasm Proteins - immunology
Neoplasms - immunology
Neoplasms - therapy
Oncology
Pathology
Review
Review Article
Ubiquitin - immunology
Ubiquitin-Protein Ligases - immunology
Ubiquitination - immunology
SummonAdditionalLinks – databaseName: Directory of Open Access Journals (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQtAUCLXIlxAWsxh7bax8LoqoqwamVerPiR8RKkNJ299B_z4yTXbo8L71FiWNZ34w9M54XY68V9CiEvBMZdWWhiwHh0AwRTsVkIUNxjrKRP322J-f69MJc3Gn1RTFhY3ngEbjD7I1XBaKKvtdOFeQv00JGsdYpVL8Tnb4o8-4YU_V2xQKVdpuyZFpwhzd4WlOgpaJEaq2kUBuSqBbs_5OW-Xuw5C8e0yqIjh-zR5MGyY_GlT9hD8qwzXaOBrSev93yN7zGdNbL8h1mz2qgN87Dl3F-tZzjI6eQjY6y0DkqrDwR2a_5nPJEpmys2112fvzx7MOJmDoliIQGyEIYU3wPfU7OoMLX2S5pmTwUnaKTScqouxRj5yLY1vkC1iQvfVYA3mYZJTxlW8PlUJ4zbmRUtp8ZxD3roj3CjtNqrfpeZ6ljw-QKtZCmMuLUzeJrqO5scGFEOiDSoSIdVMPerv_5PhbR-Ofo90SM9UgqgF1fIFuEiS3C_9iiYXsrUoZpV94EpWez1pOzt2EH68-4n8hJ0g3lcjmOMaRIQcOejZRfrwRAAzVrbthsgyc2lrr5ZZh_qTW7qc6T9m3D3q245-ey_g7Fi_uA4iV7qCgQp5VCwh7bWlwvyz5qUov4qm6aH3muFgQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Springer Nature HAS Fully OA
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9QwDLemTZp4QbDxURhTJyFeoKKJk17yeKBN00njhU3aW9SkKZwEPbjdPey_x07bmw4GEm9V60Su4zhObP8C8FpiS4uQNUVDvnKhosbC0DakMNKHChuMxnA18sWn6vxKza719Q7IsRYmJe0nSMtkpsfssPc3ZGw5T1JyHbSSoiCzu8dQ7aTbe9Pp7PPs7mSlQoZ1GypkSjT3NN5ahRJY_30e5p-Jkr9FS9MidPYIHg7eYz7t-X0MO7E7gMMp_cri-23-Jk_5nOmg_AD2L4aw-SFUlynfm7rM137-cz2nx5wzN2ouRs_Jb80Dj_4yn3O5yFCUdfsErs5OLz-eF8OFCUWgfciq0DraFtsmGE1-X13VQYlgMargjQhCeFUH72vjsSqNjVjpYIVtJKKtGuEFPoXdbtHF55Br4WXVTnRjdaOist5yt0rJtlWNUD4DMQrQhQFNnC-1-OZSVBuN64XuSOguCd3JDN5u2vzosTT-Sf2Bx2VDyTjY6cVi-cUNeuGIPSsjekn8KSMjWR9dYkNOTy1pcxYyOBpH1Q2T88ZJNZmUlmO-GZxsPtO04lhJ3cXFuqfR7E9hBs96JdhwgqiQ72zOYLKlHlusbn_p5l8TdDfDPSlbZvBuVKQ7tv4uihf_R_4SHkjOvClFIfAIdlfLdXxFrtPKHw9z5Re3YBC-
  priority: 102
  providerName: Springer Nature
Title Targeting ubiquitin signaling for cancer immunotherapy
URI https://link.springer.com/article/10.1038/s41392-020-00421-2
https://www.ncbi.nlm.nih.gov/pubmed/33436547
https://www.proquest.com/docview/2477090424
https://www.proquest.com/docview/2477500753
https://pubmed.ncbi.nlm.nih.gov/PMC7804490
https://doaj.org/article/d9592e3b2b9f482e870503d222a2096c
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LbxMxELagvXBBQHkslGiREBdYdf1c-4TSKFUVqRWCVsrNWnu9NBJs2jwOvfDbmXGcrcKjlyS767Um47E9nsc3hLxnvIVNyOiiAV25EEHyQsMxpNDMecUbHrTGbOSzc3V6KSZTOU0Gt2UKq9yuiXGhbuYebeRHTFRVadBR9_n6psCqUehdTSU0HpJ9hC5Dqa6m_XYqRKVQQ--vFcJeJq9UtMEojgBwWH-uxJKFcFBMeTUl10dLWN8xNJNh6rVgtGA7e1eE-P-XXvp3eOUfPta4dZ08IY-TzpkPN0LylDwI3TNyMOzgvP3zNv-QxyjQaF4_IOoihoZDP_nazW7WM_iZY5BHjXnrOai4uUdBWeQzzCxJ-Vu3z8nlyfhidFqk2gqFhyPLqpAymJa3jdcSVMRa1V5Qb3gQ3mnqKXWi9s7V2nFVahO4kt5Q0zDOjWqoo_wF2evmXXhFckkdU20lGyMbEYRxBrsVgrWtaKhwGaFbrlmfgMex_sUPGx3gXNsNpy1w2kZOW5aRj_071xvYjXtbH-Ng9C0RMjvemC--2zQDLZBnWOCOAX1CswALlSx5A_pRDaOvfEYOt0Np0zxe2jupy8i7_jHMQHSr1F2YrzdtJKpePCMvNyPfU8K54FjeOSPVjkzskLr7pJtdRZRvRIYSpszIp6303JH1f1a8vv9fvCGPGAbllLSg_JDsrRbr8Ba0qpUbxKkzIPvD4eTbBL6Px-dfvsLdkRoNoqUCPs9-jX8Ddfodyg
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3ZbtQw0CrlAV4QUI5AgSABLxA1PmM_IFSOakuPp620byZ2HFgJsm13V2h_im9kxjmq5ehb33I41mRm7JnxXIS8YLwGIWR0VoGunIkgeabBDMk0c17xigetMRv56FiNTsTniZxskF99LgyGVfZ7Ytyoq5nHM_IdJooiN-ioe3d6lmHXKPSu9i00WrY4CKufYLLN3-5_BPq-ZGzv0_jDKOu6CmQelPVFJmUwNa8rryUoR6UqvaDe8CC809RT6kTpnSu14yrXJnAlvaGmYpwbVVFHOcx7jVwHwZujsVdMBvEtRKHQIhjuFZbZ7Lxg8cxHcSw4h_3ucmyRCIZpl8eTc70zB3mCoaAMU70Foxlbk5WxpcC_9OC_wzn_8OlGUbl3m9zqdNx0t2XKO2QjNHfJ1m4D9v2PVfoqjVGn8Th_i6hxDEWHedKlm54tp3CZYlBJiXnyKajUqUfGPE-nmMnS5Yut7pGTK8H6fbLZzJrwkKSSOqbqQlZGViII4wxOKwSra1FR4RJCe6xZ3xU6x34b3210uHNtW0xbwLSNmLYsIa-Hb07bMh-Xjn6PxBhGYonu-GB2_tV2K94CeIYF7hjAJzQLsDHKnFegj5VAfeUTst2T0nb7xtxecHlCng-vYcWjG6dswmzZjpGo6vGEPGgpP0DCueDYTjohxRpPrIG6_qaZfotVxbESlTB5Qt703HMB1v9R8ejyv3hGbozGR4f2cP_44DG5yTAgKKcZ5dtkc3G-DE9Ao1u4p3EZpeTLVa_b36SeVLY
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3ZbtQwcFS2EuIFAeUIFAgS8ALRxkcc-wGhlnbVUlhVqJX6lsaOAyu12XYPof01vo6ZHFstR9_6lsOxJnPYM54L4DUXJW5CRkcF6sqR9ImINJohkebWKVEIrzVlI38dqr1j-fkkOVmDX10uDIVVdmtivVAXY0dn5H0u0zQ25Kjrl21YxOHO4OPFZUQdpMjT2rXTaFjkwC9-ovk2_bC_g7R-w_lg9-jTXtR2GIgcKu6zKEm8KUVZOJ2gopSr3EnmjPDSWc0cY1bmztpcW6FibbxQiTPMFFwIowpmmcB5b8F6SlZRD9a3d4eH3zpuljJVZB8s7xUV3Wx9YvUJkBJUfo6638XUMBHN1DarJxa6P8XdhQJDOSV-S84ivrJz1g0G_qUV_x3c-YeHt944B_fgbqvxhlsNi96HNV89gI2tCq3980X4NqxjUOvD_Q1QR3VgOs4Tzu3ocj7Cy5BCTHLKmg9RwQ4dsekkHFFeS5s9tngIxzeC90fQq8aVfwJhwixXZZoUJimkl8YamlZKXpayYNIGwDqsZa4te07dN86y2v0udNZgOkNMZzWmMx7Au-U3F03Rj2tHbxMxliOpYHf9YDz5nrXynyF4hnthOcInNfe4TCaxKFA7y5H6ygWw2ZEya1eRaXbF8wG8Wr5G-SenTl758bwZk5DiJwJ43FB-CYkQUlBz6QDSFZ5YAXX1TTX6UdcYp7pU0sQBvO-45wqs_6Pi6fV_8RJuo8xmX_aHB8_gDqfooJhFTGxCbzaZ--eo3s3si1aOQji9adH9DdpRWlE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+ubiquitin+signaling+for+cancer+immunotherapy&rft.jtitle=Signal+transduction+and+targeted+therapy&rft.au=Zhou%2C+Xiaofei&rft.au=Sun%2C+Shao-Cong&rft.date=2021-01-13&rft.issn=2059-3635&rft.eissn=2059-3635&rft.volume=6&rft.issue=1&rft_id=info:doi/10.1038%2Fs41392-020-00421-2&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41392_020_00421_2
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2059-3635&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2059-3635&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2059-3635&client=summon